

Principal Investigator/Program Director (Last, First, Middle): Newcomer, John W.

1
2
3
4
5
6
7
8
9
10
11
12
13
14

RO1MH072912

Protocol Version: 1.9

Revised Final for JAMA Psychiatry and clinicaltrials.gov submissions

15
16
17 **Protocol Amendment Timeline**
18
19
20

21 **Protocol 1.0 (6/22/06):**

22 First approved protocol post-funding Already had the single-patient inclusion for age under 7 & addition of
23 genetic samples prior to this
24

25 **Protocol 1.1 (08/30/07):**

26 Extra safety monitoring (3 and 9 week fasting blood draws and height/weight/WC, home urine glucose
27 monitoring kit) for participants who have impaired fasting glucose at baseline or who develop impaired fasting
28 glucose during participation; elevated triglycerides (>250 mg/dL); rapid weight gain (>10% of baseline by 6
29 weeks)
30 Changed allowable stimulant dose to 2 mg/kg/day MTP equivalent
31 Omitted 6 week fsOGTT for participants 55-93 lbs due to blood draw limitation (3 ml/kg per 2 months)
32 Added 3-month post-study follow up visit
33

34 **Protocol 1.2 (7/11/08):**

35 Changed inclusion age from 7-18 to 6-18
36

37 **Protocol 1.3 (9/18/08):**

38 Established the max blood draw as 3 mg/kg per 2 months to allow decreased minimum allowable weight for
39 children under 94 lbs
40

41 **Protocol 1.4 (7/16/09):**

42 Added diet/exercise & psychotherapy questionnaires, Family Environment Scale
43 Additional data collection from schools for grades and suspension information 12 months prior to study
44 inclusion
45

46 **Protocol 1.5 (8/24/09):**

47 Allowed concurrent treatment with atomoxetine
48 Added risk of agranulocytosis with aripiprazole
49

50 **Protocol 1.6 (7/28/10):**

51 Increase number of subjects from 240 to 325 due to high screen-failure and dropout rate
52

53 **Protocol 1.7 (10/5/10):**

54 Changed additional safety monitoring to be at PI discretion instead of limited to 3 and 9 weeks
55

56 **Protocol 1.8 (6/16):**

57 Fine-tuning analysis section to reflect that we had less missing data than expected
58 Eliminating items that were not tested/samples not run due to limited funding
59

60 **Protocol 1.9 (3/18):**

61 Clarification of primary versus secondary outcomes in the data analysis section
62
63

64 **A. Specific Aims**

65
66 The prevalence of overweight and obesity, insulin resistance and type 2 diabetes mellitus (T2DM) are
67 increasing, particularly in children, with the Centers for Disease Control warning of epidemic rates of these
68 conditions in children in the United States (US). Increased adiposity and related reductions in insulin sensitivity,
69 also referred to as insulin resistance, are major risk factors for the development of dyslipidemia, metabolic
70 syndrome, T2DM, cardiovascular disease (CVD) – e.g., risk of myocardial infarction and stroke, other adverse
71 health outcomes, and reduced psychosocial function. Reductions in lifespan attributable to obesity impact
72 younger, at-risk individuals most measurably.

73
74 Certain medications can increase regional adipose tissue mass and insulin resistance, contributing to
75 both short-term and long-term metabolic risk. Antipsychotic medications are used extensively in children, with
76 some agents producing larger increases in weight and adiposity than any other commonly used drugs in this
77 age group. Recent studies also indicate that some antipsychotics may affect insulin sensitivity independent of
78 adiposity, suggesting a potential additional mechanism for metabolic risk. The use of atypical antipsychotics in
79 children is increasing, and has been stimulated by reported efficacy for aggression and irritability in a variety of
80 childhood psychiatric disorders. However, no study in children has sensitively quantified the adverse metabolic
81 effects of these agents despite reports of alarming levels of weight gain.

82
83 **The proposed randomized clinical trial aims to assess the metabolic safety of atypical**
84 **antipsychotic agents in antipsychotic-naïve children with aggression in the setting of various**
85 **childhood psychiatric disorders during 12 weeks of prospective, randomized treatment with**
86 **olanzapine, risperidone or aripiprazole.**

87
88 **Primary Aim 1: To evaluate antipsychotic treatment effects on insulin action in skeletal muscle**
89 **(glucose disposal), liver (glucose production) and adipose tissue (lipolysis).** This study hypothesizes that
90 treatments causing greater increases in adiposity (e.g., olanzapine) will be associated with reduced sensitivity
91 to insulin effects on glucose disposal, glucose production, and glycerol/fatty acid release, in comparison to
92 treatments producing less change in adiposity (e.g., aripiprazole). Hypotheses will be evaluated by measuring
93 whole-body glucose and lipid kinetics with the use of stable isotope tracer methodology, using rate of
94 disappearance of glucose (glucose Rd; primary), rate of appearance of glucose (glucose Ra), and rate of
95 appearance of glycerol (glycerol Ra) as endpoints for the assessment of insulin sensitivity.

96
97 **Primary Aim 2: To evaluate antipsychotic treatment effects on abdominal fat mass and total**
98 **body fat.** This study hypothesizes that the selected antipsychotic medications have significantly different
99 effects on direct measures of fat mass (e.g., olanzapine > risperidone, olanzapine > aripiprazole). These
100 hypotheses will be evaluated by measuring body composition using whole body dual energy x-ray
101 absorptiometry (DEXA) and abdominal magnetic resonance imaging (MRI), quantifying percent total body fat
102 (primary) and subcutaneous and visceral abdominal fat as endpoints.

103
104 **The secondary aims** of this study will be to evaluate the effects of selected antipsychotic treatments
105 on 1) fasting plasma lipids and waist circumference, which are indirect or derivative surrogates for insulin
106 sensitivity and abdominal fat, in order to assess the extent to which changes in the primary endpoints,
107 measured directly with gold-standard tools, are also detectable using measures commonly available to
108 clinicians, 2) effectiveness for treatment of symptoms of aggression and irritability, using the Clinical Global
109 Impressions Scale (CGI) as the endpoint, and 3) (not for inclusion in the primary outcome paper) insulin
110 secretion, using frequently sampled oral glucose tolerance tests (fsOGTT) to calculate post-load area-under-
111 the-curve insulin..

112
113 **Exploratory aims include** the assessment of non-metabolic adverse events, and the assessment of
114 metabolic effects with and without concomitant stimulant therapy. Children aged 6-18 will be studied, allowing
115 exploration of age-related differences in vulnerability to treatment-induced adverse metabolic changes.

116
117 Relevant data on the primary aims are critically needed to assess the risks of antipsychotic therapy in
118 children, to identify targets for additional basic research, and to guide clinical decision-making.

120 **B. Background**

121
122 **Overview:**

123
124 Soon after the launch of the second-generation antipsychotic medications, case reports of treatment-
125 related severe hyperglycemia, hypertriglyceridemia, new-onset T2DM and diabetic complications like diabetic
126 ketoacidosis entered the psychiatric literature. Based on early adverse event signals from FDA MedWatch
127 post-marketing surveillance,¹⁻⁴ the FDA began to formally request regular updates from manufacturers
128 beginning in the summer of 2000. In January of 2001, an NIDDK/NIMH workgroup focused on the association
129 of mental disorders and diabetes incorporated evidence of antipsychotic medication effects on the risk for
130 T2DM.⁵ A recent comprehensive review of relevant reports cites three levels of evidence supporting the
131 association between antipsychotic medications and metabolic risk: 1) case reports, case series and
132 uncontrolled observational studies; 2) a series of retrospective database analyses using surrogate markers for
133 incident T2DM (e.g., ICD codes, co-prescription of hypoglycemics); and 3) a small number of controlled
134 analytic studies, including randomized clinical trials.⁶ The PI/applicant contributed to the American Diabetes
135 Association (ADA) Consensus Development Conference on this topic, which led to a position paper jointly
136 sponsored by the ADA, the American Psychiatric Association (APA), the American Association of Clinical
137 Endocrinologists (AACE), and the North American Association for the Study of Obesity (NAASO).⁷ This review
138 found “compelling evidence” that treatment with clozapine and olanzapine produces a risk of substantial weight
139 gain, and a risk of T2DM and dyslipidemia. Risperidone and quetiapine were noted to produce less weight gain
140 and discrepant results with respect to any association with T2DM or dyslipidemia, while ziprasidone and
141 aripiprazole produced the least weight gain and no apparent association with T2DM and dyslipidemia based on
142 reports to date. Unfortunately, this report and other reviews either fail to mention children or note only that the
143 relative weight gain experienced by children during treatment with antipsychotics is much larger than that
144 observed in adults, with no current evidence concerning the specific metabolic consequences associated with
145 antipsychotic treatment.

146
147 Careful studies of antipsychotic-induced metabolic changes (e.g., changes in fat versus lean muscle
148 mass, and changes in insulin action versus secretion) have just begun in adult humans. It remains unclear why
149 children are especially vulnerable to weight gain with these medications, and how such metabolic change is
150 associated with specific antipsychotics. Measurement of drug-specific treatment-induced changes in whole-
151 body and regional fat mass, and tissue-specific changes in insulin actions relevant to glucose and lipid
152 metabolism, are critical to predicting risk and planning interventions, particularly for children.

153
154 **Children, Obesity, and T2DM:**

155
156 The prevalence of obesity, insulin resistance and T2DM is increasing in the population in general and in
157 children in particular, with the Centers for Disease Control (CDC) warning that one-third of U.S. children born in
158 2000 will develop T2DM (but up to one-half of African American and Hispanic children born that year will
159 develop T2DM--Associated Press June 14, 2003). It is estimated that at least one-third of T2DM may be
160 undiagnosed (6 million individuals), out of a total prevalence of 17 million in the U.S.⁸ Prevalence increased by
161 almost 50% between 1990 and 2000,⁹ and the number of individuals diagnosed with diabetes is predicted to
162 rise from 11 million to 30 million by 2050.⁸ Currently, an additional 25 million individuals in the U.S. are
163 estimated to have insulin resistance in the form of impaired glucose control below the diagnostic threshold for
164 T2DM, typically related to increased adiposity and often accompanied by the metabolic syndrome. The
165 metabolic syndrome can include increased abdominal adiposity, insulin resistance, hyperinsulinemia,
166 hyperglycemia, dyslipidemia, hypertension, hypercoagulability, endothelial dysfunction and other features,
167 sometimes alternatively defined under the terms insulin resistance syndrome or syndrome X. The National
168 Cholesterol Education Program (NCEP) guidelines from the US Public Health Service provide the U.S.
169 definition of the metabolic syndrome used for this project. Using these criteria, it is estimated that over 20% of
170 the U.S. population, and approximately 60% of the obese U.S. population, has the metabolic syndrome.¹⁰⁻¹² In
171 addition to the well-known risk of T2DM, obesity also has other well-established adverse health consequences,
172 such as increased risk for cardiovascular disease, osteoarthritis, and breast, prostate, and colon cancers, with
173 annual attributable costs in the U.S. that exceed \$100 billion.¹³ Annual costs related specifically to diabetes
174 mellitus in the U.S. also currently exceed \$100 billion.^{14,15} Exemplifying high-cost morbidity, impaired glucose
175 control and T2DM are the major cause in the U.S. of non-traumatic amputations, blindness and end-stage

renal disease. With respect to mortality, reductions in lifespan attributable to obesity and its consequences most measurably impact younger, at-risk individuals, with severely obese 20 year-old African American males, for example, expected to lose 20 years of life.¹⁶

NCEP recognizes the metabolic syndrome as a major risk factor and T2DM as a risk equivalent for cardiovascular disease.¹² Substantial evidence indicate a progressive relationship between hyperglycemia and cardiovascular event risk (e.g., myocardial infarction, stroke), beginning at glucose levels well below diabetic thresholds.¹⁷⁻²³ These reports indicate that treatment-induced hyperglycemia can have important clinical significance even when glucose levels do not reach "impaired" or diabetic thresholds. Hypertriglyceridemia, commonly associated with insulin resistance as detailed below, is also a strong predictor of cardiovascular events,²⁴⁻²⁶ and the combination of hyperglycemia, dyslipidemia and abdominal adiposity is strongly predictive of increased cardiovascular morbidity.²⁴⁻²⁷ One of the best-established effects of adiposity on cardiovascular risk occurs via perturbations of lipid metabolism. Increased adiposity, especially increased visceral abdominal adiposity, is associated with increased small, dense low-density lipoprotein (LDL) particles and decreased high-density lipoprotein (HDL) cholesterol.²⁸⁻³⁰ Since LDL cholesterol comprises 60-70% of the total cholesterol level, total cholesterol has been used as a marker for increased LDL level in population studies. The National Health and Nutrition Examination Study III (NHANES III) provided prevalence data indicating that hypercholesterolemia (total cholesterol ≥ 240) increased with increasing BMI.³¹ These increases in cholesterol are strongly associated with increased cardiovascular risk.^{32,33} Recent meta-analyses have reported that hypertriglyceridemia is an independent risk factor for cardiovascular disease,^{34,35} and current NCEP III recommendations state that greater emphasis needs to be placed on therapeutic lifestyle changes in people with hypertriglyceridemia.³⁶

More recently, investigators have begun to assess the prevalence of the metabolic syndrome in children and adolescents. As part of the NHANES III, 2430 male and female adolescents aged 12-19 were examined for presence of metabolic syndrome.³⁷ The NCEP definition of metabolic syndrome was modified for age to include triglyceride level > 110 , HDL < 40 and abdominal obesity was defined as a waist circumference $> 90^{\text{th}}$ percentile of the sample. High fasting glucose was defined as > 110 and high blood pressure was defined as $> 90^{\text{th}}$ percentile for the sample. They found an overall prevalence of metabolic syndrome in their adolescent sample of 4.2%. It was more common in males (6.1%) than females (2.1%). In addition, 41% of the subjects had at least 1 risk factor and 14% had 2 or more. Of those adolescents who had the metabolic syndrome, 73.9% were considered overweight by their BMI, defined as $> 95^{\text{th}}$ percentile. The authors concluded that up to 30% of overweight adolescents may meet criteria for metabolic syndrome, which would translate to approximately 1 million adolescents affected in the US.

Adiposity and insulin resistance:

A key risk factor for the development of the metabolic syndrome and T2DM is increased adiposity leading to decreased sensitivity to insulin actions, often referred to as insulin resistance. There is a well-characterized progression from insulin resistance to frank T2DM. Insulin resistance can be associated with simple hyperglycemia or dyslipidemia, impaired glucose tolerance, or the full complement of changes called the metabolic syndrome. All of these conditions are characterized by decreased sensitivity to insulin actions on skeletal muscle (glucose disposal), liver (glucose production) and adipose tissue (lipolysis), with T2DM also characterized by progressive secondary disturbances in insulin secretion. Decreased insulin sensitivity at adipose tissue tends to occur later in the course of naturally occurring diabetes, but potentially early during antipsychotic treatment, characterized by an impaired ability to decrease lipolysis with corresponding increases in the release of free fatty acids (FFAs) into circulation.³⁸ Increased plasma FFA (triglyceride + glycerol) is detected clinically as an elevation in plasma triglyceride.

Using data from the National Health and Nutrition Examination Survey, Epidemiology Follow-up Study (1971-1992),³⁹ race- and sex-specific odds ratios of diabetes in relation to baseline BMI were calculated. The risk of diabetes increases as a function of BMI in all study groups. Family history, race, and ethnicity also play a role, and these variables will be measured for this project. However, substantial evidence indicates that increased central or abdominal adiposity, in contrast to femoral-gluteal fat, is a key predictor of decreased insulin sensitivity and the risk of T2DM.^{40,41} For this project, visceral and subcutaneous abdominal fat will be

measured by MRI and total body % fat will be measured by DEXA, in order to sensitively characterize changes in fat mass and measure the effect of these changes on sensitive indicators of glucose and lipid metabolism.

Insulin resistance can be caused by increases in adiposity, but insulin resistance can also contribute to subsequent increases in fat mass. The relationship between insulin and body weight regulation is in part under central nervous system control, via widely distributed central insulin receptors and insulin signaling proteins.⁴² The close relationship between insulin, lipids and adiposity is mediated in the periphery in part by lipoprotein lipase (LPL). LPL is bound to glycosaminoglycans at capillary endothelial surfaces,⁴³ with major LPL expression in adipose tissue, heart and skeletal muscle.⁴⁴ LPL can be thought of as a "gate keeper" enzyme, activated in response to hormonal (e.g. insulin), nutritional (e.g. carbohydrates), or mechanical (e.g. exercise) stimuli, which regulates the flow of fatty acids either toward muscle for oxidation or toward fat for storage depending on physiological circumstances. Skeletal muscle is usually the principal site of triglyceride clearance.⁴⁵⁻⁴⁷ However, skeletal muscle LPL activity is strongly correlated with insulin sensitivity, i.e. those who are most sensitive to insulin (and have low circulating insulin levels) have the highest levels of skeletal muscle LPL activity.^{48,49} In insulin resistant subjects with obesity, LPL activity can be elevated in adipose tissue and decreased in skeletal muscle, so that adipose tissue LPL becomes quantitatively dominant in terms of whole-body LPL activity, potentially steering additional fatty acids into fat storage. An underlying hypothesis for this project is that treatment-induced insulin resistance in children contributes to increased fatty acid storage.

Children and Antipsychotic Medication Use:

The use of antipsychotic medications in children is increasing. In addition to use in children with schizophrenia, clinical practice and recent studies have suggested additional indications, currently not approved by the FDA or fully informed by detailed risk-benefit considerations. Similar to other states, approximately 25% of the children treated with any psychotropic medication within Missouri Medicaid and the Department of Mental Health receive an atypical antipsychotic. Case reports, case series, and open label trials have described successful use of atypical antipsychotics for the treatment of aggression in children with a variety of psychiatric diagnoses.⁵⁰⁻⁵⁵ Two recent double-blind, randomized, placebo-controlled trials have demonstrated the efficacy of risperidone in reducing aggression in children with a variety of diagnoses including autism, conduct disorder, oppositional defiant disorder, attention deficit disorder, disruptive behavior disorder, as well as subaverage intelligence.^{56,57} These results are likely to further stimulate atypical antipsychotic prescriptions in children with aggression in the setting of a variety of psychiatric disorders. The proposed randomized, open-label study would address clinically relevant questions concerning both efficacy and safety in aggressive children with a variety of psychiatric disorders (see D.2. Methods).

Antipsychotic-induced changes in weight and adiposity:

While multiple environmental factors can contribute to increasing adiposity, certain medications can potentially increase regional adipose tissue mass and insulin resistance, contributing to short-term and long-term metabolic risk. For example, investigators from Washington University School of Medicine have made major contributions to the study of agents like protease inhibitors that can increase central adiposity with related adverse changes in glucose and lipid metabolism.⁵⁸⁻⁶⁰ However, these drugs receive limited use in children. In contrast, antipsychotic medications are extensively used in children and certain antipsychotics can produce greater increases in adiposity than any other commonly used drugs in this age group.

Antipsychotic treatments can produce weight gain of varying magnitude,⁶¹⁻⁶³ with more prominent effects linked to low-potency phenothiazines, clozapine,⁶³⁻⁶⁶ and olanzapine.⁶⁶⁻⁶⁸ Newer medications can have larger effects on weight gain than older agents, inducing excessive weight gain in up to 50% of adult patients,⁶⁹ with children and adolescents evidently susceptible to larger effects.⁷⁰ In general, reported weight change over specific periods of time has tended to underestimate the extent of weight gain observed with any of the medications by using last-observation-carried-forward (LOCF) data, rather than "completer" analyses.⁷¹ FDA-approved weight loss agents are generally poorly tolerated in neuropsychiatric patients (e.g., due to events like activation, insomnia, and hallucinations), and initial efforts to identify tolerable augmentation strategies to attenuate antipsychotic-induced weight gain have been disappointing.^{72,73}

Olanzapine induces clinically significant increases in short- and long-term weight gain. A comparative study of antipsychotic weight gain at 10 weeks of treatment showed a mean weight gain of 4.15 kg (9.15 lbs) with olanzapine, vs. 4.45 kg (9.81 lbs) with clozapine.⁷⁴ Within the first three months of treatment, weight increases approximate a mean of 4 kg (8.8 lbs).⁶³ Mean increases during 6-12 months of treatment with olanzapine or clozapine have been reported in the range of 14-26.4 lbs, with a mean of over 10 kg (22 lbs) at 12 months with olanzapine at 15mg/day, and individual patients experiencing 50-100 lb increases. U.S. package insert data show that 29% of patients taking olanzapine for 6 weeks (vs. 3% of placebo controls), and 56% of patients taking olanzapine long-term, gain greater than 7% of their baseline weight.

Although risperidone can produce more weight gain than some high-potency conventional agents and more than ziprasidone and aripiprazole, it produces relatively less short-term weight gain than olanzapine and clozapine,⁷⁵ ranging from 3 to 5 lbs. over the first 10 weeks of treatment.^{63,76-78} In a 6-month comparison, Tran et al reported that mean weight gain on risperidone was 5 lbs versus 9 lbs with olanzapine treatment.⁷⁹ However, longer treatment with risperidone has been associated with greater gains (9 lbs) than those reported in the Tran study.⁸⁰ Interestingly, Ganguli et al. showed mean weight *loss* of 2 lbs with risperidone at a mean treatment duration of 125.3 days in unpublished data.⁷⁷ It may be critical to control for the previous treatment received, as switches from higher weight gain liability agents to lower liability agents can be associated with weight loss. Package insert data for risperidone indicate that 18% of patients gain 7% or more of their body weight over 6-8 weeks, vs. 9% of placebo controls.

Short-term clinical trial data from the aripiprazole package labeling indicate that aripiprazole is associated with approximately 2 times the incidence of clinically significant (7% or more) weight gain compared to placebo. Pooled data from five short-term studies indicate that 4 weeks of aripiprazole treatment is associated with 0.71 kg (1.6 lbs) of weight gain, similar to haloperidol.^{81,82} Extrapolating this to 10 weeks for comparability with other agents, haloperidol is known to produce approximately 1 kg of weight increase over 10 weeks,⁶³ which may crudely approximate expected gain over the same period for aripiprazole. In a 26-week double-blind study, aripiprazole was associated with a 0.87 kg (1.9 lbs) *decrease* in weight.⁸³ Analysis of data from a 1-year double-blind study showed that aripiprazole was associated with 1.1 kg (2.4 lbs) of weight gain.⁸¹ While published data are currently sparse for this relatively new agent, results suggest that aripiprazole compares favorably to other atypical antipsychotics associated with minimal weight gain.⁸⁴

Special concerns regarding weight gain in children and adolescents

Weight gain in children can be associated with normal growth-related increases in lean muscle mass, or with increases in adiposity. The few studies in children that have attempted to address this distinction have compared treatment-induced weight gain to standardized growth curves rather than directly measuring changes in lean muscle versus fat mass, or calculating change in % body fat. Child psychiatrists have clinically noted substantial weight gain in children during antipsychotic treatment, providing anecdotal reports and early observations that this effect in children is even more pronounced than that observed in adults. However, no data are available to describe how treatment-induced changes in adiposity impact glucose and lipid metabolism in children.

The few studies that have reported changes in body weight in children treated with antipsychotics raise concern that weight gain may be significant in this treatment population. An open label study of olanzapine (mean dose 10.7 mg/day) in 25 children with pervasive developmental disorder demonstrated an average weight gain of 4.7 kg (10.3 lbs) after 12 weeks of treatment,⁸⁵ corresponding to nearly a 10% increase in body weight. Olanzapine treatment (mean dose 17.5 mg/day) of 8 psychotic adolescents resulted in an average 14% increase in body weight over an average of 9 weeks of treatment.⁸⁶ A retrospective study with 50 patients under age 18 treated with olanzapine (mean dose 13.9mg) found an average weight gain of 3.8 kilograms after an average duration of treatment of 39 days.⁸⁷ A study of 8 weeks of randomized treatment with either risperidone (up to 3 mg) or placebo in 26 children with Tourette's disorder resulted in an average weight gain of 2.8 kg (6 lbs) compared to no weight change during placebo treatment.⁸⁸ A multi-center double-blind study of 118 children ages 5-12 years with mental retardation and disruptive behaviors found a mean weight increase of 2.2 kilograms after only 6 weeks of treatment with risperidone (mean dose 1.16mg) compared to 0.9 kg with placebo.⁵⁶ A more recent study of 19 children aged 7-17 years with either Tourette's disorder or chronic motor tic disorder had an average weight gain of 1.9 kilograms over the 4-week treatment period with risperidone

(mean dose 2.5mg).⁸⁹ A similar open label study of risperidone treatment (mean dose of 1.26mg) in autistic children reported an average weight gain of 3.2 kg after 4 weeks of treatment.⁹⁰ A multi-site randomized, double blind trial of risperidone (mean dose 1.8mg) compared with placebo among 101 children ages 5-17 with autism found an average weight gain of 2.7 kilograms after 8 weeks of treatment compared to 0.8kg with placebo.⁵⁷ Sixty-three of these children treated openly for an additional 4 months had an average weight gain of 5.6 kilograms after a total 6 months, suggesting that, similar to adults, treatment effects on weight gain are not limited to the short-term.⁹¹ Finally, Sikich et al randomized 50 psychotic children and adolescents to 8 weeks of treatment with haloperidol, olanzapine, or risperidone.⁹² While significant weight gain was seen in all groups, between-group differences in weight gain and BMI were statistically significant, with olanzapine > risperidone > haloperidol. Risperidone-treated subjects had an average weight gain of 4.9 kg (10.9 lbs) compared to a mean weight gain of 7.1 kg (15.7 lbs) in olanzapine-treated subjects. All of these studies were limited by uncertain prior treatment.

Although the use of young adults rather than children might tend to minimize the effects actually observed in pediatric populations, treatment of antipsychotic-naïve first-episode schizophrenia patients may offer one of the best estimates of the potential weight gain in antipsychotic-naïve children. Recently analyzed data from an NIMH-funded study of first-episode schizophrenia patients (personal communication) suggests that olanzapine treatment is associated with a mean increase in body weight of 15.7% of baseline weight, while risperidone treatment is associated with a mean increase of 9.2% of baseline weight. Using recently analyzed data from a similar placebo-controlled first-episode schizophrenia study, aripiprazole induced a 2.7% increase in body weight from baseline (personal communication). In the absence of an available controlled antipsychotic-naïve treatment data in children, we used mean and S.D. data from these studies to estimate potential changes in percent body fat for this project.

Antipsychotic treatment and abnormal glucose metabolism:

Recent reports suggest that newer antipsychotic medications, perhaps even more than older agents, can contribute to the occurrence of clinically significant glucoregulatory abnormalities (e.g., new onset diabetes), dyslipidemia (e.g., increased plasma triglyceride) and increased weight and adiposity.⁹³ While phenothiazine treatment can contribute to abnormalities in glucose regulation, this association is not consistently observed at the same frequency for all older antipsychotics.⁹⁴ Hyperglycemia, exacerbation of existing T2DM, new onset T2DM, and diabetic ketoacidosis (DKA) have been associated with treatment using clozapine,^{2,95-116} and olanzapine.^{103,112,113,116-134} Fewer reports have been associated with quetiapine^{116,130,135-137} risperidone,^{116,138-142} and ziprasidone.¹⁴³ Random plasma glucose data from Pfizer's clinical trial dataset suggest that ziprasidone may be similar to haloperidol in the rate of associated hyperglycemia.¹⁴⁴ Aripiprazole has not been associated with published reports of impaired glucose metabolism at the time of protocol initiation, with fasting glucose and glycolated hemoglobin values comparable to placebo after 26 weeks of treatment in adults.⁸¹ Deaths have been attributed to the induction of DKA or other hyperglycemia-related events during treatment with certain atypical antipsychotics.^{2,125} The current published evidence for antipsychotic-associated hyperglycemia spans case reports and case series, FDA MedWatch data, case-control comparisons, prospective observational studies, retrospective database analyses and industry-initiated prospective randomized trials.⁶ Glick et al.¹⁴⁵ reported that 6 weeks of randomized treatment with olanzapine produced a significant increase in adiposity, weight, plasma glucose, insulin and lipid as well as homeostasis model assessment (HOMA) insulin resistance,^{146,147} in comparison to no significant change in these measures during ziprasidone treatment. Case reports suggest that children may be just as vulnerable to hyperglycemia during treatment with atypical antipsychotics.^{1,148-150} The limited data from children precluded any mention of this at-risk group in the recent report from the ADA's Consensus Development Conference addressing second generation agents, co-sponsored by APA, AACE and NAASO.⁷

Insulin resistance with and without weight gain during antipsychotic treatment:

Weight gain producing increased visceral adiposity can increase insulin resistance and contribute to hyperglycemia,^{40,151} so that treatment-related changes in glucose regulation are expected secondary to changes in adiposity. However, approximately 20-25% of cases of new onset T2DM in schizophrenia patients may occur in the absence of weight gain, suggesting potential direct effects on insulin secretion or action in a smaller subset of patients.^{2,93,95,96,104,123,129} Recent studies also suggest the potential for drug effects on insulin

sensitivity independent of adiposity. Using fasting and post-load plasma measures from modified oral glucose tolerance tests (fsOGTTs), the P.I. and colleagues have reported that clozapine and olanzapine may be associated with disturbances in glucose regulation independent of differences in adiposity.¹⁵² Similarly, a recent euglycemic clamp study in Wistar rats demonstrated acute impairments in insulin sensitivity associated with olanzapine and clozapine administration.¹⁵³ Henderson and colleagues¹⁵⁴ reported similar results with a frequently sampled intravenous glucose tolerance test (fsIVGTT) using Bergman's Minimal Model (MINMOD) analysis in subject groups similarly matched for adiposity, age and race.¹⁵⁵⁻¹⁶⁰ MINMOD analyses have been used to assess insulin sensitivity and "glucose effectiveness" when gold-standard techniques are not possible.^{156,157,160-162} The perspective gained to date in adults suggests commonly occurring, treatment-induced and largely adiposity-related increases in insulin resistance, with less consistent changes in insulin resistance independent of adiposity, and smaller or more sporadic defects in insulin secretion. Reports of sporadic cases of deaths associated with DKA underscore that large defects in insulin secretion may occur in some patients. No data are available from children to inform a similar understanding of the pattern of metabolic change during antipsychotic therapy. It is not clear at this time whether children experience primarily adiposity-related changes in glucose and lipid metabolism, or to what extent adiposity-independent effects may play a role. The answer to these questions is directly relevant to future efforts to establish prevention and intervention strategies to lower long-term metabolic risk for T2DM and CVD in children.

Antipsychotic treatment and abnormal lipid metabolism:

In early studies, phenothiazine treatment was associated with increases in measured plasma lipids.¹⁶³ Recent reports have similarly identified clinically significant increases in plasma triglycerides in patients treated with clozapine,¹⁶⁴⁻¹⁶⁶ olanzapine,^{124,167-169} and quetiapine.¹⁶⁷ Pfizer assessed fasting plasma triglycerides during brief randomized treatment with several newer and older antipsychotic agents¹⁴⁴ with groups ranging in size from 27 to 34 subjects. They reported increases in fasting plasma triglycerides during olanzapine, quetiapine and thioridazine treatment, and decreases during ziprasidone, risperidone and haloperidol treatment. A similar pattern of minimal effect on plasma lipids and other elements of the metabolic syndrome has been observed for aripiprazole during 26 weeks of randomized treatment, in comparison to both placebo and olanzapine.¹⁷⁰ While case reports indicate that children may also be vulnerable to abnormalities in lipid metabolism during antipsychotic treatment, no controlled or detailed studies have been performed.¹⁷¹

Interrelationship between lipid and glucose metabolism: The mechanism underlying treatment-related increases in circulating triglyceride levels remains unknown, but is hypothesized to involve changes in adiposity leading to decreased insulin sensitivity at adipocytes. Plasma lipoproteins are commonly classified as chylomicrons, very low density lipoproteins (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL) based on their flotation in an ultracentrifuge. VLDL, produced by the liver, is the major endogenous triglyceride-rich lipoprotein. Triglycerides represent 65% of the lipids in VLDL particles and are formed by esterification of free fatty acids delivered to the liver from plasma, free fatty acids released from intrahepatic triglycerides, and fatty acids made *de novo* by the liver (*de novo* lipogenesis). Increased production of VLDL apoB and triglyceride is often causally related with hypertriglyceridemia associated with insulin resistance in other conditions.¹⁷²⁻¹⁷⁴ Interrelationships between insulin, glucose, and fatty acid metabolism in regulating VLDL production are complex. Important basic methodological issues remain to be addressed in this patient population. Changes in adiposity can be strongly related to differences in lipid metabolism and circulating plasma lipoproteins. The most sensitive measure of treatment effects on glycerol and fatty acid kinetics is not changes in circulating plasma triglyceride levels, a complex function of rate-limiting hepatic apoB production and VLDL export, but rather a direct measure of glycerol and fatty acid kinetics as proposed in this application.

C. Significance:

T2DM and CVD are important disease targets for the NIH and the U.S. Public Health Service, with overweight and obesity, hyperglycemia and dyslipidemia identified as major modifiable risk factors. These risk factors can be altered by adverse changes in nutritional status and activity level, and by adverse medication effects. The identification of factors that contribute to the increased prevalence of medical illnesses such as T2DM and CVD in patients with major mental disorders is similarly a high priority. The critical evaluation of adverse events, as well as efficacy, is required for new medications seeking new on- or off-label indications. To our knowledge, the proposed Metabolic Effects of Antipsychotics in Children (MEAC) study would be the only

NIH funded study concerning adverse medication effects on direct measures of key metabolic risk factors for cardiovascular disease and T2DM in children (i.e., insulin sensitivity and adiposity). The broad generalizability of the results will be enhanced by the study of children with aggressive behaviors in the setting of a variety of disorders, with and without concomitant stimulant treatment.

Noted above, the recent ADA/APA Consensus Development Conference report concerning second generation antipsychotic medications makes no mention of use in children and no recommendations for risk management, due to the lack of relevant information from treated children. Relevant data are critically needed to assess the risks as well as benefits of antipsychotic therapy in children, identify needs for additional basic research, as well as guide administrative and regulatory decision-making.

D. Research Design & Methods

1. Study Site Resources and Timetable:

The proposed experiments will be conducted using existing dedicated research space at Washington University School of Medicine, including the Adult and Pediatric General Clinical Research Centers (GCRC), Diabetes Research and Training Center (DRTC) and Clinical Nutrition Research Unit (CNRU) where all previously reported experiments have been performed.

Year 1:

- a. Subject recruitment;
- b. Screen visit, (**Study Visit 1**) for 156 subjects;
- c. Baseline evaluations (**Study Visits 2 and 3**) for 33 subjects;
- d. 6-week post treatment evaluations (**Study Visit 4**) for 26 subjects;
- e. 12-week post treatment evaluations (**Study Visits 5 and 6**) for 19 subjects;
- f. Plasma sample analyses for substrate concentration and isotopic enrichment; data entry.

Year 2:

- a. Subject recruitment;
- b. Screen visit, (**Study Visit 1**) for 300 subjects;
- c. Baseline evaluations (**Study Visits 2 and 3**) for 66 subjects;
- d. 6-week post treatment evaluations (**Study Visit 4**) for 66 subjects;
- e. 12-week post treatment evaluations (**Study Visits 5 and 6**) for 66 subjects;
- f. 3-month post 12-week study evaluations for subset of subjects (Study Visit 7) estimated 22-42 subjects. Estimate is based on needs of current subjects: 17 out of 57 enrolled subjects (30%) vs 17 out of 27 subjects who have completed the study (63%);
- g. Plasma sample analyses for substrate concentration and isotopic enrichment; data entry

Year 3:

- a. Subject recruitment;
- b. Screen visit, (**Study Visit 1**) for 300 subjects;
- c. Baseline evaluations (**Study Visits 2 and 3**) for 66 subjects;
- d. 6-week post treatment evaluations (**Study Visit 4**) for 66 subjects;
- e. 12-week post treatment evaluations (**Study Visits 5 and 6**) for 66 subjects;
- h. 3-month post 12-week study evaluations for subset of subjects (Study Visit 7) for estimated 22-42 subjects;
- h. Plasma sample analyses for substrate concentration and isotopic enrichment; data entry.

Year 4:

- a. Subject recruitment;
- b. Screen visit, (**Study Visit 1**) for 300 subjects;
- c. Baseline evaluations (**Study Visits 2 and 3**) for 66 subjects;
- d. 6-week post treatment evaluations (**Study Visit 4**) for 66 subjects;
- e. 12-week post treatment evaluations (**Study Visits 5 and 6**) for 66 subjects;
- f. Plasma sample analyses for substrate concentration and isotopic enrichment; data entry.

- 509 g. 3-month post 12-week study evaluations for subset of subjects (Study Visit 7) for estimated 22-42
510 subjects;
- 511 h. Plasma sample analyses for substrate concentration and isotopic enrichment; data entry.
- 512 Year 5:
- 513 a. No additional subject recruitment;
- 514 b. No additional Screen visits (**Study Visit 1**);
- 515 c. Baseline evaluations (**Study Visits 2 and 3**) for 33 subjects;
- 516 d. 6-week post treatment evaluations (**Study Visit 4**) for 40 subjects;
- 517 e. 12-week post treatment evaluations (**Study Visits 5 and 6**) for 47 subjects;
- 518 f. Plasma sample analyses for substrate concentration and isotopic enrichment; data entry.
- 519 g. 3-month post 12-week study evaluations for subset of subjects (Study Visit 7) for estimated 22-42
520 subjects;
- 521 h. Plasma sample analyses for substrate concentration and isotopic enrichment; data entry.
- 522 i. Complete all data coding and entry; complete all final data analysis, write up results, presentation(s).
- 523

524 2. Subjects:

525

526 We will enroll 325 eligible subjects with clinically significant aggression symptoms, as defined by a score of ≥ 18
527 on the Irritability subscale of the Aberrant Behavior Checklist^{205, 206} in the context of one or more Axis I DSM
528 IV207 childhood psychiatric disorders, including conduct disorder, oppositional defiant disorder, disruptive
529 behavior disorder, autism, pervasive developmental disorder, attention deficit disorder, bipolar affective
530 disorder and schizophrenia, who assent to participate and whose guardian(s) give informed consent for
531 participation in the study. Individuals with clinically significant suicidal ideation will not be included. We plan on
532 screening up to four times the enrollment target number in order to achieve recruitment targets (**Study Visit 1**).
533 All subjects will be 6-18 years of age and will include all races and ethnic groups **and both genders**, with
534 targeted enrollment reflecting the overall gender distribution of males and females for “externalizing” disorders
535 (i.e., 2.5:1, male:female).²⁰⁸ By initially enrolling 108 subjects in each of 3 treatment groups described below,
536 we estimate this will enable us to obtain a study population of 80 subjects per group for a total of 240
537 analyzable subjects who complete the protocol (assuming 10% attrition). Recruitment will involve targeted
538 community outreach to pediatricians, schools and family support groups, as well as screening potential
539 subjects from the Child and Adolescent Psychiatry Clinic and the Barnes Jewish Christian¹⁷⁵ Behavioral Health
540 System which have a combined annual total of 2,464 individual patients with a large number of potentially
541 eligible subjects.

542

543 The inclusion criteria are: i) age 6-18 years ii) generally healthy and a score of ≥ 18 on the Aberrant Behavior
544 Checklist for irritability in the context of one or more Axis I DSM IV childhood psychiatric disorder, including
545 conduct disorder, oppositional defiant disorder, disruptive behavior disorder, autism, pervasive developmental
546 disorder, attention deficit disorder, bipolar affective disorder and schizophrenia; iii) Children’s Global
547 Assessment Scale (CGAS) Score ≤ 60 ; iv) not previously treated with an antipsychotic; individual subjects with
548 a remote (i.e., > 1 year), brief (i.e., < 1 week) prior antipsychotic exposure may be considered for enrollment on
549 a case by case basis; v) patient assent and informed consent obtained from the parent or guardian; vi) no
550 clinically significant (PI determination) changes in permitted medications (e.g., stimulants, SSRI’s) for
551 approximately 1 month prior to Baseline Evaluations;

552

553 The exclusion criteria are: i) active suicidality or a primary diagnosis of major depressive disorder; ii) any
554 lifetime use of antipsychotics; individual subjects with a remote, brief remote prior antipsychotic exposure may
555 be considered for enrollment as above; iii) the presence of any serious medical disorder that may confound the
556 assessment of relevant biologic measures or diagnoses, including: significant organ system dysfunction;
557 endocrine disease, including type 1 or type 2 diabetes mellitus; coagulopathy; anemia; or acute infection; all
558 based on PI discretion; iv) subjects regularly taking within the last 3 months any glucose lowering agent, lipid
559 lowering agent, exogenous testosterone, recombinant human growth hormone, or any other endocrine agent
560 that might confound substrate metabolism, oral glucocorticoids (glucocorticoid nasal spray and inhalers are
561 permitted), sedating antihistamines (non-sedating antihistamines such as but not limited to Claritin (loratadine)
562 and Zyrtec (cetirizine) are permitted), and certain mood stabilizing agents, as some medications may

563 themselves worsen or otherwise alter weight gain, glucose and lipid regulation or otherwise make it difficult to
564 assess the effects of the antipsychotic alone; (note that exposure to many psychotropic agents including
565 stimulants and SSRI's is permitted in order to maintain the generalizability of the sample); v) IQ < 70 (based on
566 school records and/or evaluation by clinician); vi) current substance abuse; vii) past history of, or current
567 dyskinesia; viii) stimulant dosage significantly higher (per PI) than the equivalent of approximately 2 mg/kg/day
568 methylphenidate equivalent dose.

570 **Rationale for Inclusion and Exclusion Criteria:** The CGAS score corresponds to definite impairment that
571 requires clinical intervention. Intelligence quotient cut-off is to ensure that subjects can comprehend the
572 assessment questions. In order to aid recruitment, multiple psychiatric disorders including attention deficit
573 disorder, bipolar affective disorder, conduct disorder, oppositional defiant disorder, and disruptive behavior
574 disorder will be included, as long as participants meet screening criteria for aggression and are not actively
575 suicidal or primarily depressed. Substance use disorders are excluded to avoid confounding mental status
576 examinations and/or measures of metabolic factors. Stimulant drugs at a stable dose are permitted for some of
577 the research subjects as at least half of these subjects will have comorbid ADHD. Not allowing stimulants
578 would therefore likely decrease recruitment and would provide ecologically valid data. Children cannot be on a
579 stimulant dosage significantly higher than the clinical standard of no more than 2mg/kg/day equivalent of
580 methylphenidate. We choose to also study subjects off stimulants, in order to explore the effect of stimulant
581 therapy on adiposity gain and metabolic change.

583 **Subject recruitment and retention:** Potential subjects will be recruited by Clinical Research Coordinator's in
584 our unit, under the direction of the PI, from the clinics listed above, with additional outreach to sources such as
585 pediatrician's offices and the school systems as needed. The names and contact numbers of these families will
586 be sent to the PI and Clinical Research Coordinators, to do a telephone screen to rule out children who are
587 unlikely to have the inclusion criteria or who have exclusion criteria. Those families not excluded by telephone
588 screen will be given appointments for baseline assessments. Once subjects are enrolled, research staff will
589 maintain at least weekly contact with subjects and relevant family members. The PI's Clinical Research
590 Coordinators and staff have extensive experience working with neuropsychiatric populations and their families
591 and efficiently performing recruiting, screening, and follow-up to maintain subject flow and high follow-up rates.
592 Retention in this project will be further enhanced by the use of highly experienced clinicians, providing
593 medication adjustments and monitoring, as well as supportive psychotherapy, throughout the course of the 12-
594 week study (weekly visits for the first 4 weeks, followed by every other week visits for the final 8 weeks, with
595 additional visits available as needed).

597 **Subjects with Attention-Deficit Hyperactivity Disorder (ADHD) Not Already on Stimulants:** If, at
598 screening or during baseline, children are suspected of or diagnosed with ADHD, but are not already on
599 treatment, they will be referred back to their community physicians for treatment. If the treatment is with a
600 stimulant, and if the treatment has not alleviated the aggressive behaviors, these children can be referred back
601 for the metabolic study of antipsychotic therapy. Reasons for excluding non-stimulant ADHD treatments and for
602 the maximum dose of stimulant are provided above.

605 3. Study Outline and Randomization Plan:

607 All 240 eligible, recruited subjects completing the **Screen Visit (Study Visit 1)** will be randomized to
608 prospective open-label treatment with one of three atypical antipsychotic medications. Specifically, a) 80
609 subjects will be randomized to open-label treatment with aripiprazole; b) 80 subjects will be randomized to
610 open-label treatment with risperidone; c) 80 subjects will be randomized to open-label treatment with
611 olanzapine. Recruitment and randomization will be further structured to target having half of the children in
612 each treatment group aged 6-12, and half aged 13-18, using separate randomization schedules for each age
613 group. In addition, within each of the 2 age groups in each of the 3 treatment conditions, recruitment and
614 randomization will be further structured to target having half of the children on previously prescribed and
615 ongoing stimulant therapy, and half not receiving stimulants. This plan targets the acquisition of 20 younger
616 subjects on stimulants and 20 younger subjects off stimulants, as well as 20 older subjects on stimulants and
617 20 older subjects off stimulants, within each of the antipsychotic treatment groups. Targeted group size is

618 based on power estimates, described below, which will permit hypothesis testing for treatment group
619 interactions with age and with stimulant therapy. Group composition will otherwise be monitored and matched
620 to the greatest extent possible for disease severity, specific age, and ethnicity, by over-recruiting any under-
621 represented groups identified in the active enrollment phase.

622
623 Randomized subjects will have **Baseline Evaluations (Study Visits 2 and 3)**, followed by assessments at **6**
624 **weeks (Study Visit 4)** and **3 months (Study Visits 5 and 6)** as described below and summarized in **Table 1**
625 below. The 6-week (**Study Visit 4**) follow-up evaluation after the treatment change is selected to provide
626 sufficient time for only initial changes in adiposity, glucose and lipid metabolism, without larger changes in
627 adiposity predicted at this point in children. The 3-month follow-up is selected to measure predicted changes in
628 adiposity, along with metabolic parameters. DXA scans at 6 weeks (**Study Visit 4**) and 3 months (**Study Visit**
629 **5**) will allow percent total body fat to be quantified for use as a covariate in the study analyses. The 3-month
630 follow-up will include the MR scan (**Study Visit 5**) repeated from baseline, as sufficient time will have elapsed
631 to permit larger changes in adiposity. Flexible antipsychotic dosing in the longitudinal follow-ups will enhance
632 clinical outcomes and allow the possibility of exploring effects of dose, although there is currently no evidence
633 for dose-dependent effects. Adverse events and aggression symptoms are rated, to assess status at baseline
634 (**Study Visit 2**) and 12-weeks (**Study Visit 6**), during the isotope clamp protocol. In addition, the Modified
635 Adverse Event Checklist will be used during weekly contacts with all subjects. In order to evaluate clinical
636 response to post-study recommendations, there will be a 3-month post study follow-up visit (**Study Visit 7** -
637 approximately 3 months after the end of the 12-wk study) for a subset of subjects who have had increases in
638 metabolic risk factors (e.g. 10% or greater increase from baseline body weight, fasting triglyceride levels ≥ 250
639 mg/dl at 6 or 12 weeks, and/or a fasting or post-load glucose ≥ 100 or 140 mg/dl, respectively, at 6 or 12
640 weeks).

641
642 **Quality of Care** During the randomized treatment phase of the study, subjects will continue to receive care
643 from their primary physician, with extensive supplemental contacts and monitoring as outlined above so that all
644 subjects are monitored at a level that exceeds the standard of care. This site has extensive experience in the
645 performance of clinical studies in children with psychiatric disorders, including interactions with children with
646 acute and sometimes psychotic illness. This site also has extensive experience in performing complex
647 metabolic assessments in pediatric populations, as well as in psychiatric patients with severe psychotic
648 illnesses, maintaining an outstanding safety record and high retention rate in all of these endeavors.

649
650 **Choice of Specific Treatment and Experimental Conditions:** The antipsychotic medications selected for
651 this project were chosen in order to compare specific newer antipsychotic medications needed to address the
652 study questions, where the use in child populations is either well supported by current literature and/or the drug
653 is used extensively for the treatment of aggression based on national and state prescribing patterns or showing
654 rapid growth for this indication. Olanzapine and risperidone are the most frequently prescribed antipsychotic
655 medications for aggression associated with psychiatric illness, with aripiprazole use increasing. Olanzapine is
656 associated with the greatest amount of weight gain and metabolic effects in reports to date, making it an ideal
657 positive control in this study. Risperidone is widely used in this population, and is the best supported by
658 published literature, with intermediate weight gain and metabolic effects among the newer medications.
659 Aripiprazole, most recently approved by the FDA, appears to have a favorable side effect profile in children,
660 especially with respect to weight gain and minimal metabolic effects in adults. Although we could have chosen
661 ziprasidone, concerns about QTc prolongation may have complicated recruitment and currently in the state of
662 Missouri, aripiprazole is used in children within the Department of Mental Health at approximately twice the
663 rate of ziprasidone. It is predicted to see extensive use in children in the coming months and years.
664 Aripiprazole's favorable metabolic side effect profile in preclinical and early clinical trials make it a good
665 candidate for a negative treatment control in this study.

4. Specific screening tests and procedures:

Table 1: Planned procedures

	MAGIC	Medical Exam/ ECG	Fasting Labs	fsOGTT	DXA Scan	MRI	Isotope Clamp	Hours of Participation
Study Visit 1 (Screen)	X							4-5
Study Visit 2 (Baseline)		X	X	X	X	X		3.5
Study Visit 3 (Baseline)							X	8
Study visit 3A Extra safety visit at 3 wks			X					1
Study Visit 4 (6-weeks)			X for subjects ≥ 93 lbs	X for subjects 94+ lbs	X			2.5
Study visit 4A Extra safety visit at 9 wks			X					1
Study Visit 5 (12-week end of study)			X	X	X	X		3.5
Study Visit 6 (12-week end of study.)	X						X	8
Visit 7, 3-mo. post study follow-up for subset of subjects.			X					1

Medical examination and history: All subjects will be screened with a detailed history and physical examination performed by a study physician, routine blood tests including a glycated hemoglobin (A1C) level, and resting 12-lead electrocardiogram.

Assessment of Clinically-Available Parameters: fasting labs and anthropomorphic measures: In addition to the exploratory aim of assessing non-metabolic adverse events, a secondary aim of the study is to assess the extent to which changes in the primary endpoints, measured directly with gold-standard tools, are also detectable using surrogate or derivative measures that are commonly available to clinicians. For example, an indirect surrogate indicator of insulin sensitivity is triglyceride/HDL ratio.¹⁷⁶ Routine blood tests will be performed including A1C, complete blood count with differential, comprehensive metabolic panel,, and a fasting lipid panel. Blood pressure and a measure of waist circumference will also be obtained. Waist circumference is used to indirectly assess abdominal fat. Some studies have suggested the utility of anthropomorphic measures as proxies for abdominal fat as measured by abdominal computed tomography (CT), although concerns about reliability remain.¹⁷⁷⁻¹⁷⁹

Body composition analyses: Body composition will be evaluated at baseline, 6 weeks, and 3 months. Percent total body fat and percent total fat-free mass will be determined by DXA (Hologic QDR 1000/w, Waltham, MA).^{180,181} The error of regional fat free mass determination by this technique, as compared with computerized tomography, is less than 5%.^{180,181}

Magnetic resonance images of the abdomen will be obtained at baseline and 3 months to directly quantify abdominal (subcutaneous and intra-abdominal) adipose tissue mass.¹⁸² Images will be acquired on a 1.5-T superconducting magnet (Siemens, Iselin, NJ) using a T₁-weighted pulse sequence with a TR of 500 msec and TE of 12 msec. The imaging matrix will be 256x256, and section thickness will be 8 mm with a 2mm intersection gap. Consistent slice localization will be accomplished by using a rigid landmark (i.e., the iliac crest) to position the subject in the machine and by using coronal scouting images to identify the site for image acquisition (i.e., the L₃-L₄ interspace). Three cross-sectional images at the level of the umbilicus, one above,

and one below the umbilicus section, will be obtained. Twenty-three slices are analyzed by selecting the first 8 sequential slices beginning at the inferior pole of the most superior kidney and continuing inferiorly. Visceral (VAT) and subcutaneous (SAT) adipose tissue surface area (cm^2) are calculated for each slice and reported as a mean value over the 8 slices. The image analysis will be performed by using NIH image software and a program constructed in the Mallinckrodt Institute of Radiology.

Isotope infusion clamp: Participants will be instructed to begin fasting, except for water, at 2000 the night before the study assessment, following a standard meal provided by their parent or caregiver. The following morning at approximately 0600, participants will be admitted to the Pediatric Clinical Research Unit for the clamp procedure. At approximately 0700, a catheter will be inserted into an antecubital vein of one arm to infuse stable isotopically labeled glucose, dextrose and insulin. Another catheter will be inserted into a contralateral hand or forearm vein heated to 55 °C using a thermostatically controlled hand-warming box to obtain arterialized blood samples.¹⁸³ At approximately 0800, prior to beginning the tracer infusion, blood samples will be taken to obtain baseline measurements of glucose and glycerol enrichments. Then, a 3-h primed-constant infusion of $[6,6\text{-}^2\text{H}_2]\text{glucose}$ in 0.9% NaCl solution (22 $\mu\text{mol}/\text{kg}$ prime and $0.25 \mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ infusion rate) will be used to determine basal glucose kinetics. After 120 min of tracer glucose infusion, a 1-h primed-constant infusion of $[1,1,2,3,3\text{-}^2\text{H}_5]\text{glycerol}$ (1.2 $\mu\text{mol}/\text{kg}$ prime and $0.08 \mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ infusion rate) will be used to determine basal glycerol kinetics. After the 180 minute basal tracer infusion period, a euglycemic, hyperinsulinemic clamp will be initiated and continued for 180 minutes.¹⁶¹ During the clamp, insulin will be infused at a rate of $40 \text{ mU}\cdot\text{m}^{-2}\cdot\text{min}^{-1}$ for 180 minutes (initiated with a two-step priming dose of $160 \text{ mU}\cdot\text{m}^{-2}\cdot\text{min}^{-1}$ for 5 min followed by $80 \text{ mU}\cdot\text{m}^{-2}\cdot\text{min}^{-1}$ for 5 min), to achieve plasma insulin concentrations of approximately 90 $\mu\text{U}/\text{ml}$. This plasma insulin concentration provides an optimal level for evaluating insulin's effect on glucose production and lipolysis.¹⁸⁴ Euglycemia will be achieved by infusing a variable rate of 20% dextrose enriched to approximately 2.5% with $[6,6\text{-}^2\text{H}_2]\text{glucose}$ to minimize changes in plasma glucose tracer to trace ratio.¹⁸⁵ The infusion of $[6,6\text{-}^2\text{H}_2]\text{glucose}$ will be decreased by 50% of basal from 180-360 minutes to account for the expected decline in hepatic glucose production.^{186,187} The infusion of $[1,1,2,3,3\text{-}^2\text{H}_5]\text{glycerol}$ will also be decreased by 50% of the basal rate during the clamp to account for the expected decline in whole-body lipolytic rate.¹⁸⁸ Blood glucose will be measured every 5-10 minutes during the clamp procedure to inform adjustments to the dextrose infusion rate, using either a glucose oxidase method via a glucose analyzer (Yellow Springs Instruments, Yellow Springs, Ohio 45387 USA) or a validated portable blood glucometer when necessary to decrease the total amount of blood drawn in smaller individuals. Blood samples will also be collected every 10 min during the last 30 min of both the basal period and the insulin clamp periods to determine glucose and glycerol isotopic enrichments and the determination of glucose and glycerol kinetics, {Korenblat, 2008 #19307} {Deivanayagam, 2008 #19305} {Magkos, 2009 #19308} as well as plasma hormone (insulin, C-peptide, glucagon, growth hormone, epinephrine, norepinephrine, free fatty acid and leptin) concentrations. For children < 77 lbs, collection of plasma catecholamines, growth hormone, free fatty acid and leptin will be restricted to limit total blood draws to no greater than 3 ml/kg body weight.^{183,189} Insulin-stimulated percent change for glucose and glycerol kinetics (Glucose Ra and Rd, Glycerol Rd) will be calculated as the absolute value of the difference between the kinetic rate calculated during insulin-stimulated versus basal conditions. The resulting value will be divided by the basal condition and multiplied by 100%. Primary Aim 1 endpoints from the isotope clamp protocol are: 1) Insulin-stimulated % change in Glycerol Ra; 2) Insulin-stimulated % change in Glucose Ra and 3) Insulin-stimulated % change in Glucose Rd.

Frequently-sampled oral glucose tolerance test (fsOGTT)(Secondary analysis, not for inclusion in the primary outcome paper): At baseline, 6 weeks and 3 months, after an overnight (12 h) fast, blood samples for plasma glucose, insulin, C-peptide, epinephrine, norepinephrine, glucagon, cortisol, concentrations will be obtained immediately at 0 (baseline), 10, 20, 30, 60, 90, and 120 min after ingesting a 75 g oral glucose load.¹⁹⁰ The new criteria of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus will be used to determine subject eligibility. Area under the curve insulin will be used as the endpoint in the secondary aim concerning treatment effects on insulin secretion. Subjects under 94 lbs will have fasting labs instead of a 6-week fsOGTT to decrease total blood volume drawn over 2-months.

5. Psychiatric/Medical Diagnostic Assessment Methods:

751 **General Considerations and Time Frames:** Instruments were selected to be comprehensive and to permit
752 comparability to those used in other studies in federally funded research projects in child psychiatry. At
753 baseline, the time frame will be lifetime. At follow-up appointments, the time frames will be the three-month
754 interval since the prior assessment.

755 **Need for Both Parent and Child Informants for Assessment of Child Psychopathology:** In child
756 psychiatry research, parent and child informants are both needed due to poor mother-child concordance.¹⁹¹⁻¹⁹⁹
757 Parent and child reports will be combined by using the most severe rating given by either, in accordance with
758 the work of Bird et al.²⁰⁰ Second informants for child aged subjects are usually biological mothers. If the mother
759 is incapacitated (e.g., hospitalized for suicide attempt), the father or other guardian who lives with the child is
760 the second informant. Different raters are used for the mother and child within each family. Scientifically this is
761 important to avoid bias from knowing what the other informant has reported. This procedure also aids
762 recruitment and retention, because families greatly appreciate mother and child interviews conducted in
763 parallel by two raters, as this saves them time in the research unit.

764 **Missouri Assessment of Genetics Interview for Children (MAGIC):** The MAGIC interview is a semi-
765 structured standardized psychiatric diagnostic interview with six versions: Child, Adolescent, Young Adult and
766 Adult are self-report versions, and the Parent and Parent of Young Adult are parent reports on siblings. The
767 MAGIC is a revised version of the Diagnostic Interview for Children (5). All MAGIC versions are computerized
768 for simultaneous administration and data entry. The MAGIC uses criteria of the DSM-III-R, DSM-IV and ICD-10
769 to diagnose child, adolescent, young adult, and adult psychiatric disorders. The interview can be administered
770 by telephone or in person. A current paper version exists for all interviews should one be needed. The
771 average length of time to administer the MAGIC is 2 hours for adults and 90 minutes for children or
772 adolescents. The MAGIC has a lengthy companion specifications manual (Appendix 2) that is used to maintain
773 consistency of administration across interviewers and across studies. An in-depth, 6-week training course with
774 practice sessions is required for all interviewers, followed by a qualifying certification by an experienced
775 certified interviewer or by one of the MAGIC authors. Diagnostic algorithms have been created, tested, and
776 verified. The DSM-IV diagnoses include domain impairment and duration requirements. The specific sections
777 included in the MAGIC interviews are: Demographics, Attention Deficit/Hyperactivity Disorder, Oppositional
778 Defiant Disorder, Conduct Disorder, Alcohol Abuse, Tobacco and Glue-Sniffing Abuse, Marijuana and Street
779 Drug Abuse, Gambling, Depression, Mania, Dysthymia, Separation Anxiety, Panic Disorder, Phobias,
780 Generalized Anxiety Disorder, Obsessive Compulsive Disorder, Posttraumatic Stress Disorder, Eating
781 Disorders, Premenstrual Dysphoric Disorder, Somatization, Psychosis and Schizophrenia, Psychosocial
782 History, Home Environment, Peer and Sibling Relationships, Perinatal History, and Health Services Usage.
783 Reliability and prospective stability studies have been completed on the MAGIC; in particular, for diagnosis of
784 ADHD, inter-rater reliability for the Child, Adolescent, and Parent versions was excellent, ($\kappa > .9$ for DSM-
785 IV ADHD subtype diagnoses as well as for the endorsement of the 18 individual DSM-IV Criterion A ADHD
786 symptoms). The 18-month prospective stability (done with raters blinded to the initial diagnosis) for a diagnosis
787 of ADHD was also good ($\kappa = .78$); κ s for population-defined ADHD subtypes including inattentive and
788 combined subtypes were .76 and .67, respectively (6).

791 **Achenbach Child Behavior Checklist/Adult Behavior Checklist (CBCL/ABCL):** The CBCL/ABCL serves as
792 a general screening measure of behavior problems, competencies, and school functioning, and has well-
793 established norms. It obtains reports from parents, other close relatives, and/or guardians regarding children's
794 competencies and behavioral/emotional problems. A shorter version of the CBCL/ABCL was created for the
795 large Missouri sibship study, which does not include 20 competence items covering the child's activities, social
796 relations, and school performance. These shortened versions will be used for this project. The revised
797 CBCL/ABCL has 113/126 items that describe specific behavioral and emotional problems, plus one open-
798 ended item for reporting additional problems. Parents rate their child for how true each item is now or within the
799 past 6 months using the following scale: 0 = not true (as far as you know); 1 = somewhat or sometimes true; 2
800 = very true or often true. The subscales scored from the CBCL are Aggressive Behavior; Anxious/Depressed;
801 Attention Problems; Rule-Breaking Behavior; Social Problems; Somatic Complaints; Thought Problems; and
802 Withdrawn/Depressed. The six DSM-oriented scales are: Affective Problems; Anxiety Problems; Somatic
803 Problems; Attention Deficit/Hyperactivity Problems; Oppositional Defiant Problems; and Conduct Problems.

Wechsler Intelligence Scale for Children, Version 4 (WISC-IV): To confirm the exclusion of mental retardation and to give a general estimate of intellectual ability all participants will be administered the Vocabulary subtest of either the WISC-IV (children/adolescents) or Wechsler Adult Intelligence Scale (WAIS-III)²⁰¹. Normal scoring protocols will be used to create a standardized score.

Aberrant Behavior Checklist:^{202,203} This instrument is a five-factor scale comprising 58 items under the categories of (I) Irritability, Agitation, Crying; (II) Lethargy, Social Withdrawal;²⁰⁴ Stereotypic Behavior; (IV) Hyperactivity, Noncompliance; and (V) Inappropriate Speech. The 15-item Irritability subscale includes questions about aggression, self-injury, tantrums, agitation, and unstable mood on a scale of 0 to 45. It has been estimated that our cut-off of ≥ 18 on this subscale will identify individuals that are 1.3 to 1.5 SD above the mean.^{205,206}

Social Responsiveness Scale (SRS): The SRS is a 65-item questionnaire with a 4-point rating scale (“Not true” to “Almost always true”) designed for use by parents and/or teachers in which ratings of the frequency of typical autistic symptoms across all three DSM-IV symptom domains are obtained. It measures the severity of autism spectrum symptoms as they occur in natural social settings. The SRS provides a clear picture of a child’s social impairments, assessing social awareness, social information processing, capacity for reciprocal social communication, social anxiety/avoidance, and autistic preoccupations and traits. It is appropriate for use with children from 4 to 18 years of age. The SRS has a major advantage over other instruments used to assess autism spectrum conditions. Rather than providing a “yes or no” decision about the presence of symptoms of a given disorder, the SRS measures impairment on a quantitative scale across a wide range of severity, from sub-clinical to severe—which is consistent with recent research indicating that autism is best conceptualized as a spectrum condition rather than an all-or-nothing diagnosis. Unlike most questionnaire instruments, SRS scores are highly correlated between parents and teachers (0.75-0.80), have minimal age differences in distribution, and show high test-retest reliability for at least 17 months (0.7-0.85). In addition, there are minimal associations between intelligence and SRS scores (correlations on the order of 0.1 to 1.2 in both normal and autistic children).

Children's Global Assessment Scale (CGAS):^{207,208} This instrument is a global measure of severity based on psychiatric symptomatology and impairment of adaptation in family, social, school, and work areas. On this scale 0 is worst, 100 is best, and ≤ 60 is definite clinical impairment.

Clinical Global Impressions Scale (CGI): The CGI scale²⁰⁹ is widely used in psychopharmacology research across the age span. It will be completed by a blinded rater. At baseline, the severity measure is used. At post-baseline assessment times, severity and improvement scales are used. At all time points, a severity score of 1 or 2 is little or no impairment, a score of 3 is mild and a score of ≥ 4 is moderate or greater psychopathology. At the three-month assessment, scores of 1 or 2 are fully or almost fully recovered, score of 3 is minimal recovery and scores of ≥ 4 are almost no improvement or worsened from baseline. This is the endpoint for the secondary aim concerning effectiveness for symptoms of aggression.

Pubertal Status Questionnaire (PSQ):²¹⁰ This instrument is completed by subjects at least 10 years old. The PSQ has demonstrated high reliability with physical examination. Rather than a physical exam, the PSQ relies on participant self-report of Tanner Stage by endorsement of the appropriate cartoon representation of the respondent’s pubertal status. The PSQ has been accepted by the Washington University IRB for the evaluation of pubertal status.

Modified Study Side Effects Scale (SE): This scale collects data on side effects such as sedation, galactorrhea and gynecomastia, and has been used in multiple NIH funded treatment studies.

Abnormal Involuntary Movement Scale (AIMS): This instrument is administered to the child and has been modified to include instructions on how to examine for cogwheeling and tongue dyskinesias in children.

Barnes Akathisia Scale (BAS): This instrument is administered to the child for the assessment of akathisia.

Simpson-Angus Scale (SAS): This instrument is administered to the child for the assessment of pseudoparkinsonianism.

861
862 **Medical Records (MR) and Medical History Form:** This information is obtained by telephoning to obtain
863 mailing or faxing preference and then mailing or faxing consents to the various physicians, other health care
864 providers, and hospitals. Consents accompany mailing materials with prepaid return postage or with
865 instructions for faxing materials back to the investigators. The Medical History Form is administered to the
866 mother about the child.

867
868 **Locator Form:** This form is completed at baseline to enhance the ability to locate subjects at the three-month
869 follow-up. This form includes: (1) Social security numbers of the subject and each parent. (2) Work and home
870 telephone numbers and addresses of both biological parents, step-parents and parents residing outside of the
871 household. (3) Names, telephone numbers, and addresses of spouses, significant others, siblings,
872 grandparents, close friends and neighbors of the participants. (4) The name, address and telephone number of
873 the participant's school, and their teacher's name, as well as a check box option asking whether it is
874 acceptable to contact the school. In our experience families do not object to supplying this information and
875 understand that it will only be used to locate them without -under any circumstance- revealing why the
876 University is looking for them other than that they are study participants.

877
878 **Diet and Exercise Behaviors Questionnaire:**

879 This retrospective phone questionnaire will assess participants' dietary habits and activity levels during the
880 course of participation, and related changes. Study participants and their guardians will be given a 17-item
881 questionnaire adapted from diet and exercise questionnaires used in similar research studies.^{211 212 213 214 215}
882^{216 217 218 219 220} Parents of subjects age 12 and under will be asked to complete the questionnaire, and, for
883 subjects age 13 and up, the parent will be the default recipient of the questionnaire as well. Parents of
884 subjects ages 13 and up will be asked at the beginning of the questionnaire whether their teenager has a
885 significantly better idea of their own diet and exercise patterns, and, if they answer yes, their teenager will be
886 contacted and asked verbal consent for the diet and exercise questionnaire at a later time. For subjects who
887 have already enrolled in the MEAC study, consent will be implied via continuation of the phone interview, and
888 verbal consent will be asked at the beginning of the phone call as well. All newly enrolled subjects will be
889 formally consented for permission to be contacted during or after study participation. Subjects will be reminded
890 that participation is voluntary, that their participation in the main MEAC study will be unaffected if they choose
891 not to participate in this questionnaire, and that they may choose not to answer any question or end their
892 participation in this segment at any time.

893
894 **Psychotherapy Attitudes and Perceptions Questionnaire:**

895 This retrospective phone questionnaire will assess parental attitudes and experiences with psychotherapy, and
896 how these points of view might influence their decision to participate in optional family/individual psychotherapy
897 offered to all study participants at the time of enrollment. Only guardians will be asked the 22-item
898 questionnaire, adapted from questionnaires assessing attitudes and perceptions towards psychotherapy in
899 similar studies of children with psychiatric diagnoses.^{221 222 223 224 225} For subjects who have already completed
900 the MEAC study, consent will be implied via continuation of the phone interview. All newly enrolled subjects
901 will be formally consented for permission to be contacted during or after study participation. Subjects will be
902 reminded that participation is voluntary, that their participation in the main MEAC study will be unaffected if
903 they choose not to participate in this questionnaire, and that they may choose not to answer any question or
904 end their participation in this segment at any time.

905
906 **Family Environment Scale:**

907 To characterize the family's perception of expressed emotion within the family during study
908 participation, the Family Environment Scale (FES) will be included. FES form R,²²⁶ which measures
909 perceptions of family environment, is a 90 question True/False questionnaire with ten total scoring
910 domains encompassing relationship (Cohesion, Expressiveness, Conflict), personal growth
911 (Independence, Achievement Orientation, Intellectual-Cultural Orientation, Active-Recreational
912 Orientation, Moral-Religious Emphasis), and system maintenance (Organization, Control). Caregivers
913 of newly-enrolled MEAC subjects will be given the FES over the phone at baseline and in paper form

at the 3-month time point. Caregivers of patients who have already completed the MEAC study will be given the FES once as a retrospective phone questionnaire.

Establishing DSM-IV Diagnoses: All research materials (assessment instruments, school reports, agency records, pediatrician/medical charts), are reviewed in consensus conferences to establish final diagnoses.

STUDY ASSESSMENT INSTRUMENTS		
Instrument	Second Informant	Child
Missouri Assessment of Genetics Interview for Children (MAGIC)	X	X
Child Behavioral Checklist	X	
WISC-IV		X
Aberrant Behavior Checklist	X	
Social Responsiveness Scale	X	
Children's Global Assessment Scale	X	X
Clinical Global Impressions Scale	X	X
Missouri Adolescent Female Twin Study (MOAFTS), trauma subscale	X	X
Duke Pubertal Status Questionnaire		X
Modified Side Effects Scale	X	X
Abnormal Involuntary Movements		X
Barnes Akathisia Scale		X
Simpson-Angus Scale		X
Medical History Form	X	
Locator Form	X	
Diet and Exercise Behaviors Questionnaire:	X	X
Psychotherapy Attitudes and Perceptions Questionnaire:	X	X
Family Environment Scale	X	

Blinding, Training and Maintaining Interrater Reliability of Research Clinicians: Raters are blind to treatment group assignment. Families will be instructed not to reveal the drug that child has been on. This has worked well in multiple other studies. Research staff are trained to interrater reliability and recalibrated annually. Raters have virtual 100% agreement on diagnostic categories and symptom severity ratings five times in a row as both interviewer and observer.

Appointment Times and Reimbursements for Effort and Inconvenience: Reimbursements will be paid at a level commensurate with similar studies in the St. Louis area. Free parking is provided in a safe underground area. Each family receives reminder phone calls in the days and weeks prior to the follow-up visit from the research study staff.

6. Blood for Future Genetic Studies

Blood samples for future genetic studies will be obtained. These will only be obtained from families who specifically give permission on a separate genetic study consent form. These consent forms (child and parent/related guardian (e.g. grandparent)) will be separate from that of the metabolic study to reinforce that participation in the metabolic study does not mandate participation in the genetic study. Separate consents are also needed to accommodate the special language required in consent forms for genetic studies. For families consenting to future genetic studies, an RNA sample (2.5ml) will be obtained from the child at baseline and at 12 weeks. DNA samples, 10 ml each, will be obtained from the child and both parents when possible. All genetic samples will be stored at -80°C until processed or for up to 20 years. The samples will be labeled only with the subject study ID number.

7. Plasma Assays:

All analytical procedures are routinely performed in Washington University laboratories including the GCRC Core Laboratory.

a. Plasma metabolites: Plasma glycerol and glucose will be recovered in the aqueous fraction following solvent extraction of plasma lipids and converted to the HFB derivative for GC/MS. Plasma glucose concentration will be determined by the glucose oxidase method. Plasma and microdialysis glycerol concentrations will be determined by an enzymatic assay (Sigma). Plasma insulin and C-peptide,²²⁷ glucagon²²⁸ and cortisol²²⁹ concentrations will be measured by radioimmunoassay. Plasma catecholamine concentrations will be determined by a radioenzymatic method developed by our GCRC core laboratory.²³⁰ Amino acids will be isolated from plasma by cation exchange chromatography and converted to HFBPr derivatives²³¹ for GC/MS. Plasma fatty acids will be recovered by solid phase extraction as recently described, and analyzed by GC/MS and quantitative GC.²³² VLDL will be isolated from 3 mL of fresh plasma by ultracentrifugation at $d=1.006\text{ g/mL}$ and stored at -70°C for further processing. VLDL triglyceride concentrations will be determined by enzymatic assay (Sigma Chemical Co., St. Louis, MO). TG will be isolated from the lipid extract by TLC, and fatty acids recovered as methyl esters and glycerol recovered as the HFB derivative for GC/MS analysis as previously described.^{233,234}

b. GC/MS analyses of glycerol: Enrichment of HFB- $[\text{}^2\text{H}_5]$ glycerol will be measured by electron impact (EI) by monitoring a fragment (M-O-HFB, $m/z\ 467/472$) which retains all 5 initial deuteriums in the $[\text{}^2\text{H}_5]$ glycerol tracer. Washington University investigators have recently demonstrated that by incorporating concentration dependency into a standard curve approach one can decrease between-run variation in values to $<1\%$.²³⁵ HFB-glycerol and glucose will be analyzed by EI using ions at $m/z\ 467/472$ ($[\text{}^2\text{H}_5]$ glycerol) and $m/z\ 519/521$ ($[\text{}^2\text{H}_2]$ glucose). For all GC/MS analyses, instrument response will be calibrated using standards of known enrichment.

8. Calculations

a. Whole-body substrate (glycerol and glucose) Ra and Rd: During isotopic and physiologic steady state, Steele's steady state equation²³⁶ will be used to calculate substrate Ra and Rd. Steele's non-steady-state equation²³⁶ will be used to calculate substrate Ra during metabolic non-steady state conditions.

b. Whole body substrate oxidation: The rate of fat and glucose oxidation will be calculated using the stoichiometric equations described by Frayn.²³⁷

9. Data Management and Analysis Techniques:

Data management and quality control: The data management and quality control process will begin with the initial design of data collection forms (when needed) and data capture forms in SPSS (IBM SPSS; Armonk, NY). Quality control measures will include the flagging of out-of-range and inappropriately missing data items, the identification of forms that have not been completed for a particular subject, and confirmation that enrolled subjects satisfy eligibility criteria. To further ensure accurate and complete data, all data collection personnel will be asked to review forms as soon as they are filled out so that problems related to missing or illegible data items can be quickly corrected. Because forms will include the initials of the data collection person who completed the form, it will be easy to contact the appropriate individual when problems are identified.

991
992 **Data analysis:** Primary and secondary analyses for adiposity and insulin sensitivity outcomes were conducted
993 using Intent-to-Treat (ITT) analyses (IBM SPSS; Armonk, NY) including randomized subjects. Primary
994 outcomes were change in DEXA-measured adiposity (DEXA % total fat) and clamp-derived insulin sensitivity
995 at muscle (percent change in Glucose Rd), with secondary outcomes of change in MRI measured adiposity
996 and percent change in Glucose Ra and Glycerol Ra. Primary analysis for change in DEXA % fat used a
997 likelihood-based mixed-effects model using time (0, 6 and 12 weeks) and medication group as independent
998 variables, with Toeplitz covariance structure specified, based on Bayesian information criteria (BIC). The
999 primary outcome analysis for insulin sensitivity, as well as the secondary outcome analyses for adiposity and
000 insulin sensitivity, used repeated-measures analyses of covariance (ANCOVA) with baseline values of the
001 dependent variables as the covariate (to address potential baseline influence on outcomes) and time and
002 treatment condition as independent factors, testing for time by treatment condition as well as covariate
003 interactions. When time by treatment interactions were significant, contrasts were used to test comparisons of
004 interest; when not significant, treatment condition was removed from the model to calculate the main effect of
005 time and any interactions. MRI abdominal fat models were run with compartment (subcutaneous versus
006 visceral) as an additional 2-level factor, to test for time by compartment and time by treatment by compartment
007 interactions. Exploratory analyses tested whether the effects of age, stimulant use, gender and race altered
008 primary results, re-running primary analyses with an additional two- or three-level factor (e.g., yes/no
009 stimulant); these exploratory analyses were corrected for multiple tests (Bonferroni; $0.05/4 = 0.0125$). Other
010 exploratory analyses used ANCOVA as above (week 0 and 12) to support interpretation of primary/secondary
011 measures (e.g., DEXA lean, clamped insulin concentration) or for clinical context (e.g., BMI %ile, psychiatric
012 symptoms), with ANOVA used to test the effect of time within individual treatment groups. Effect sizes
013 (Cohen's d) were calculated for primary and secondary outcomes.
014

015 Exploratory analyses include correlating the 12 week change in measures of insulin sensitivity and the
016 corresponding change in percent fat with a view towards a more precise understanding of the degree to which
017 changes in insulin sensitivity can be explained by changes in fat mass. Analyses of covariance that employ
018 changes in insulin sensitivity as the dependent variable and include changes in percent fat as a predictor will
019 provide estimates of the percent of variability explained (R^2) both by the change in fat mass alone and by the
020 combination of this measure and the covariates already noted. These analyses will also provide information
021 about the degree to which the covariates are independently predictive of changes in insulin sensitivity. Other
022 exploratory analyses will involve the role of regulatory hormones such as cortisol, glucagon, and leptin. Since
023 these hormones will be measured at baseline and at 6 and 12 weeks, mixed model repeated measures
024 analysis of variance will evaluate the effect of treatment on these hormones and will provide information about
025 the pattern of change during the 12 week follow up period. A final set of possible analyses will involve the use
026 of logistic regression to determine factors that are associated with the presence of metabolic syndrome at
027 baseline, to be performed only if baseline levels are meaningful. While we will also use logistic regression to
028 explore factors that are predictive of the development of metabolic syndrome during follow-up and will evaluate
029 between group differences in the incidence of syndrome development, we do not anticipate that large numbers
030 of subjects who do not have this syndrome will develop it during the relatively brief 12-week follow-up. Thus,
031 we expect that the statistical power associated with these latter analyses will be small and view them as
032 exploratory hypothesis generating analyses.
033

034 In all of the analyses we perform, we will give careful attention to the appropriateness of the statistical
035 procedures that are employed. Thus, all analyses will be preceded by graphical assessments of the data to
036 evaluate the distribution of particular variables and to determine whether outliers are present. When we
037 perform analyses of covariance, we will routinely evaluate regression residuals to ensure that the model is
038 appropriate. Similarly, we will evaluate the Hosmer-Lemeshow goodness of fit statistic to assess the
039 appropriateness of logistic regression models. When variables are poorly distributed and assumptions for a
040 given analytic procedure are violated, we will explore and implement remedial measures that include data
041 transformations and semi-parametric approaches based on the ranks of the data if satisfactory data
042 transformations cannot be found. We have defined only two primary specific aims with the primary comparison
043 being baseline to 12 weeks both because of the importance of those aims and to minimize multiple
044 comparisons concerns. Because of the multiple comparisons issue, p-values associated with the secondary
045 and exploratory analyses we perform will be interpreted cautiously as hypothesis-generating rather than as
046 hypothesis-confirming.

Sample size and statistical power: The target sample size is 80 subjects in each of the three study groups. Prior data from young adults (i.e., NIMH and industry funded first episode studies where change in % body fat may be crudely estimated from known change in body weight and the assumption that increases occur in body fat rather than lean muscle), which may underestimate changes in children, suggests that percent body fat increases of $10 \pm 4\%$ may occur in the olanzapine group, $5 \pm 4\%$ in the risperidone group and $0 \pm 4\%$ in the aripiprazole group (e.g., 10 lbs fat increase in a 70 lb subject who starts at 20% body fat yields 30% body fat). Based on this, the power for a two-sided test at the 0.05 level of significance to compare any one group with any other group will be essentially 1. This substantial power will permit us to test hypotheses about changes in percent body fat in important subgroups that are defined by age, gender, race, and whether the subject is or is not taking stimulants (e.g., planned younger off-stimulant subgroup sample size is 20), as well as explore other predictors. Because we do not have reliable prior data on likely pooled baseline to endpoint or between-group differences in insulin sensitivity measures like the glucose disappearance rate, we base our power computations on the effect size that is detectable with 80 subjects per group. Using a two-sided test at the 0.05 level of significance, the target sample size implies that we can detect a between group difference in the mean disappearance rate equal to half of a standard deviation with a power of 0.88.

A secondary interest of the proposed research will be whether the younger prepubescent children between the age of 6 and 11 respond differently from children between the ages of 12 and 18. In our existing clinic system, a sample of 527 children who had the study eligible diagnostic codes indicated that 69.3% were in the younger age group. Even assuming a worst-case scenario that we fail in our planned efforts at over-recruitment to the older age groups and that these percentages continue as we recruit for the planned study, we anticipate that in each study arm, we will have about 56 subjects in the younger age group and 24 in the older age group. With these numbers and using within group analyses, we will have a power of 0.81 to detect a response rate difference in an outcome measure in younger as compared to older individuals that is 70% of a standard deviation, with the power increasing to 0.90 if the effect size is 80% of a standard deviation. If there are no statistical interactions between treatment group and age category, it will be reasonable to combine all three groups in asking about age-related differences so that worst case sample sizes will be 168 in the older group and 72 in the younger group. This dramatically increases statistical power to the extent that we will be able to detect an effect size equal to 40% of a standard deviation with probability of 0.81. The power increases to 0.94 under this no interaction assumption if the effect size comparing age differences is 50% of a standard deviation.

E. Human Subjects

Protection of Human Subjects

1. Risks to the subjects:

a) Human Subjects Involvement and Characteristics:

We will enroll 325 eligible subjects with clinically significant aggression symptoms, as defined by a score of ≥ 18 on the Irritability subscale of the Aberrant Behavior Checklist^{205, 206} in the context of one or more Axis I DSM IV207 childhood psychiatric disorders, including conduct disorder, oppositional defiant disorder, disruptive behavior disorder, autism, pervasive developmental disorder, attention deficit disorder, bipolar affective disorder and schizophrenia, who assent to participate and whose guardian(s) give informed consent for participation in the study. Individuals with clinically significant suicidal ideation will not be included. We plan on screening up to four times the enrollment target number in order to achieve recruitment targets (**Study Visit 1**). All subjects will be 6-18 years of age and will include all races and ethnic groups **and both genders**, with targeted enrollment reflecting the overall gender distribution of males and females for “externalizing” disorders (i.e., 2:1, male:female).²⁰⁸ By initially enrolling 108 subjects in each of 3 treatment groups described below, we estimate this will enable us to obtain a study population of 80 subjects per group for a total of 240 analyzable subjects who complete the protocol (assuming 10% attrition).

The inclusion criteria are: i) age 6-18 years ii) generally healthy and a score of ≥ 18 on the Aberrant Behavior Checklist for irritability in the context of one or more Axis I DSM IV childhood psychiatric disorder, including conduct disorder, oppositional defiant disorder, disruptive behavior disorder, autism, pervasive developmental disorder, attention deficit disorder, bipolar affective disorder and schizophrenia; iii) Children's Global Assessment Scale (CGAS) Score ≤ 60 ; iv) not previously treated with an antipsychotic; individual subjects with a remote, brief prior antipsychotic exposure may be considered for enrollment by the PI on a case by case basis; v) patient assent and informed consent obtained from the parent or guardian; vi) no clinically significant (based on PI determination) changes in permitted medications (e.g., stimulants, SSRI's) for approximately 1 month prior to Baseline Evaluations based on PI discretion;

The exclusion criteria are: i) active suicidality or a primary diagnosis of major depressive disorder; ii) any lifetime use of antipsychotics; individual subjects with a remote, brief prior antipsychotic exposure may be considered for enrollment on a case by case basis by the PI; iii) the presence of any serious medical disorder that may confound the assessment of relevant biologic measures or diagnoses, including: significant organ system dysfunction; endocrine disease, including type 1 or type 2 diabetes mellitus; coagulopathy; anemia; or acute infection; all based on PI discretion; iv) subjects regularly taking within the last 3 months any glucose lowering agent, lipid lowering agent, exogenous testosterone, recombinant human growth hormone, or any other endocrine agent that might confound substrate metabolism, oral glucocorticoids (glucocorticoid nasal spray and inhalers are permitted), sedating antihistamines (non-sedating antihistamines such as but not limited to Claritin (loratadine) and Zyrtec (cetirizine) are permitted), and certain mood stabilizing agents, as some medications may themselves worsen or otherwise alter weight gain, glucose and lipid regulation or otherwise make it difficult to assess the effects of the antipsychotic alone; (note that exposure to many psychotropic agents including stimulants and SSRI's is permitted in order to maintain the generalizability of the sample); v) IQ < 70 (based on school records and/or evaluation by clinician); vi) current substance abuse; vii) past history of, or current dyskinesia; viii) stimulant dosage significantly higher (per PI judgment) than the equivalent of approximately 2 mg/kg/day methylphenidate equivalent dose.

All recruited subjects meeting inclusion/exclusion criteria will have Baseline Evaluations, followed by assessments at 6 weeks and 12 weeks. Subjects will be randomized to prospective treatment with one of 3 newer atypical antipsychotic medications that currently are either used extensively in children, or are showing rapid growth or growth potential in this population. Specifically: a) 40 subjects who have never been treated with an antipsychotic will be randomized to open-label treatment with risperidone (Risperdal). Of those subjects, 20 will be under the age of 11 years, 6 months and 20 subjects will be over the age 11 years, six months; b) 40 subjects who have never been treated with an antipsychotic but are receiving a stimulant will be randomized to open-label treatment with risperidone (Risperdal). Of those subjects, 20 will be under the age of 11 years, 6 months and 20 subjects will be over the age 11 years, six months; c) 40 subjects never treated with an antipsychotic will be randomized to open-label treatment with aripiprazole (Abilify). Of those subjects, 20 will be under the age of 11 years, 6 months and 20 subjects will be over the age 11 years, six months; d) 40 subjects who have never been treated with an antipsychotic but are receiving a stimulant will be randomized to open-label treatment with aripiprazole (Abilify). Of those subjects, 20 will be under the age of 11 years, 6 months and 20 subjects will be over the age 11 years, six months; e) 40 subjects never treated with an antipsychotic will be randomized to open-label treatment with olanzapine (Zyprexa). Of those subjects, 20 will be under the age of 11 years, 6 months and 20 subjects will be over the age 11 years, six months; f) 40 subjects receiving a stimulant but who have never treated with an antipsychotic will be randomized to open-label treatment with olanzapine (Zyprexa). Of those subjects, 20 will be under the age of 11 years, 6 months and 20 subjects will be over the age 11 years, six months.

b) Sources of Materials:

Research materials will be obtained by psychiatric interview, physical exam, medical record review, observation, indirect calorimetry by using a metabolic cart and a ventilated hood system (Vmax 29, SensorMedics, Yorba Linda, CA), DXA and MR imaging of body tissue, and collection of whole blood, as described in the Experimental Design Methods section of this application. The specimens will be obtained solely for research purposes. Although these generally will be obtained specifically for the purposes of the study, use will be made, where appropriate, of existing records and data obtained as part of routine clinical care. Study samples and data sheets will be coded with an identification number for each subject. All of the

156 data from individual subjects will be maintained confidentially and their names and identities will not be
157 disclosed in any published document.

158
159 **c) Potential Risks:**
160

161 There are no physical risks associated with the psychiatric diagnostic and assessment procedures or clinical
162 ratings. Some subjects may find the questions to be boring or difficult to answer and thus mildly distressing.
163 Minimal risks exist for the collection of sensitive information on subjects. Although we will not ask about sexual
164 function in this study, subjects will be asked by a physician or nurse to complete a Pubertal Status
165 Questionnaire (PSQ). This is an IRB approved, age-appropriate questionnaire used to assess pubertal status.
166 The potential physical risks of this study are small. The risks of blood drawing and catheter insertion include
167 discomfort, minimal bleeding or infection at the site of insertion. However, sterile technique will be used and
168 subjects with coagulopathy will be excluded. Prior to phlebotomy or placement of an intravenous catheter, a
169 topical anesthesia will be offered to participants to minimize pain at insertion site and decrease the
170 psychological affect associated with any invasive phlebotomy or intravenous catheter placements. The
171 associated side effects of the topical anesthesia are very rare. The most common side effects are irritation,
172 redness, itching, or rash. These side effects usually do not require medical attention. Regardless of the
173 severity, a physician will evaluate all side effects. The risks of infusing stable isotope tracers include the
174 possibility of pyrogen response or infection. However, all solutions are tested for pyrogens and sterility before
175 infusion and are administered under strict aseptic conditions. There are no known short- or long-term risks
176 associated with the infusion of the isotopes themselves. The risks of euglycemic clamping are transient hyper-
177 or hypoglycemia that might lead to nausea, headache or feeling sweaty or shaky, however, glucose levels are
178 very closely monitored and kept within ± 10 mg/dl of a target of 95 mg/dl, so that such adverse events have not
179 occurred in any of the approximately 300 clamps conducted by the P.I. to date. The risks of DXA scanning
180 include discomfort while lying on the scanning table, and low-dose x-ray exposure (less than a standard chest
181 film). There are no known direct risks of MR scanning in the absence of having some metal in the body, a basis
182 for exclusion from this aspect of the study. Some people who feel uncomfortable in small or confined spaces
183 may feel similarly when they are positioned in the MR machine or under the indirect calorimetry ventilated
184 hood. The hood may also cause some feelings of discomfort such as being too warm and/or facial sweating.
185 The patients who are randomized to an antipsychotic medication will not do this exclusively for the purpose of
186 this study, but for some clinical indication, and thus any risk associated with this switch is part of their routine
187 clinical care, rather than research. Thus, they may be at risk for clinical adverse events associated with the
188 newly started treatment, including the risk that their symptoms do not respond as well or temporarily worsen.
189 The potential risk that subject reimbursement could be experienced as coercive has been addressed and
190 minimized per our IRB. The cost for reimbursing subjects is based on our experiences recruiting patients into
191 studies of similar complexity and inconvenience to subjects, with this level of reimbursement approved by our
192 IRB and consistent with that of other similar projects in children at this institution. In addition, this project will be
193 conducted on our GCRC, where a further layer of protection for human subjects is in place in the form of the
194 Research Subject Advocate (RSA) Program, directed by NIH (NCRR) guidelines. The GCRC RSA will closely
195 monitor this project, including the obtaining and maintenance of informed consent, through routine meetings
196 with subjects and parents and attendance at some of the planned study visits.

197
198 **2) Adequacy of Protection Against Risks**
199

200 **a) Recruitment and Informed Consent:**
201

202 All key personnel involved in the design and conduct of the research involving human subjects will
203 receive the required education on the protection of human research participants prior to funding of this project.
204 Procedures to recruit subjects for the protocol and obtain their informed consent are conducted and supervised
205 by the P.I. Targeted educational and recruitment in-services will be conducted at all appropriate facilities in
206 order to make providers and administrators aware of this project and to assist in identifying eligible subjects.
207 Clinicians and administrators at these sites are informed about the purpose, procedures, risks, and benefits of
208 the protocol, as well as the inclusion and exclusion criteria, so that they can best discuss the research project
209 with individual patients/guardians that might be eligible and interested, and make appropriate referrals for study

screening. The P.I. or Collaborators will discuss the study, including the risks and benefits of participation, with relevant potential subjects, their guardians, and relevant family members to obtain informed consent from interested individuals. Informed consent will be obtained from the patient/guardian whenever possible, or with assent from the patient and consent from the guardian. Guardians will be included in all informed consent processes. The consent form, which incorporates HIPAA authorization, contains a description of the purpose and procedures, risks, procedures to minimize them, and possible benefits. Subjects (and their guardians) are assured that they are free to withdraw consent and discontinue participation without prejudice to their current or future medical care. The objectives of the project, all of the requirements for participation, and any possible discomforts and risks will be clearly explained to the subjects orally and in writing in lay terms which they are able to comprehend. The subject/guardian must sign an informed consent form, approved by the Washington University School of Medicine Institutional Review Board, before they can participate in the study.

b) Protection Against Risk:

The risks of breaching confidentiality will be strictly limited by the use of locked and restricted access to data as well as numbers rather than names in the database that will be created for this project. No identifiers will be included in any computer files or reports generated by this study. All key personnel involved in the design or conduct of research involving the human subjects will receive the required education on the protection of human research participants prior to funding of this project.

Metabolic Measures-The discomfort associated with blood drawing or catheter placement is usually mild and brief; should it persist, participation will be discontinued. All blood will be drawn on the General Clinical Research Center (GCRC), a well-staffed medical inpatient and outpatient facility within the Washington University Medical Center. The risk of adverse events during the blood drawing and IV access procedures will be monitored by the nurse, who is in attendance at all times; treatment is facilitated by the extensive medical resources available on the GCRC. The risks of blood drawing and catheter insertion will be minimized by use of sterile technique and the exclusion of subjects with coagulopathy. The risks of infusing stable isotope tracers will be minimized by testing all solutions for pyrogens and sterility before infusion and will be administered under strict aseptic conditions. The risks of euglycemic clamping will be minimized by monitoring glucose levels very closely and keeping them within ± 10 mg/dl of a target of 95 mg/dl; no such adverse events have occurred in any of the approximately 300 clamps conducted by the P.I. to date. Should the need for medical attention arise, all the resources of a large teaching hospital are available for subject evaluation and treatment. Complete physical examinations will be performed to screen out subjects who may be at potential risk. The infusion studies will be conducted under the supervision of a licensed physician. The GCRC is equipped with a defibrillator and all appropriate emergency medications. Subjects with known or suspected heart disease will not be accepted into the study. A resting ECG will be obtained and read by a physician prior to the start of the studies. Any significant ECG abnormality at rest will lead to automatic exclusion of the subject from the project. Prior to participation in the MR scan, subjects are carefully screened for the presence of any metal objects in their body; the presence of metal objects are a basis for exclusion from this part of the study. Any physical or emotional discomfort with any procedures will be handled by allowing patients to stop and rest, or discontinue the procedure whenever they desire. Subjects enrolled into the randomized open-label treatment with risperidone, olanzapine, or aripiprazole will be chosen carefully in collaboration with treating physicians and psychiatrists, so that antipsychotics are added with adequate titration schedules and careful dose selection. These subjects will be closely monitored by their primary treating physician and supervised by Drs. Newcomer, Nicol, and Haupt, in order to minimize any adverse effects of adding antipsychotic therapy. Clinical care will be supplemented to a level above what is routine in clinical practice, using weekly safety visits either in person or via phone by the research staff in collaboration with Ms. Schweiger. Close follow-up will enhance compliance with prescribed medications and rapid clinical response to difficulties or need for medication adjustment. Subjects with increased risk factors at baseline or who have developed increased risk factors during the 12-weeks of study medication will have added study visits at 3-weeks and/or 9-weeks and will be given a home monitoring kit for weekly testing. (See Data and Safety Monitoring Plan). A Data and Safety Monitoring Committee has been developed for this protocol.

3-month post study follow-up for a subset of subjects completing the 12-week study

To assess end of study recommendations to parents and treating clinicians, a subset of subjects will be evaluated who have had increases in metabolic risk factors (e.g. 10% or greater increase from baseline body weight, fasting triglyceride levels greater than or equal to 250mg/dL at 6 or 12-weeks and /or a fasting or post-

load glucose of greater than or equal to 100 mg/dL or 140 mg/dL, respectively, at 6 or 12-weeks). Each subject will be evaluated individually for these criteria at the end of the 12-week study to determine which subjects would meet criteria for an additional safety visit. Those subjects meeting criteria and consenting/assenting would be scheduled for an interim medical history and measurement of weight, height, waist circumference, fasting glucose and fasting lipid profile. Clinically significant abnormal findings would be discussed with the parent(s) and relevant clinicians.

Behavioral Assessments- Only highly trained research staff or physicians will be utilized to collect data and these individuals will be experts in confidential and professional interaction with study participants. Participants will be informed in the informed consent document that any suicidal or homicidal information obtained from a child/adolescent will be shared with parent(s) to protect the life of the child/adolescent. If a child/adolescent is found to be suicidal or homicidal during any evaluation, the individual performing the evaluation will immediately notify the parent or guardian and will contact one of the study physicians. The research staff will provide the family with appropriate mental health care referrals, if the family does not already have a mental health caretaker. If the suicidal or homicidal participants are 18 years old, precautions and referrals will be given directly to the participant and to the participants' adult household members. If the participant is the sole adult household member and suicide/homicide is not deemed to be imminent, precautions and referrals, including emergency room contacts, will be provided. If any participant is deemed to be imminently suicidal and/or homicidal, 911 will be contacted as soon as possible. Participants will also be informed in the informed consent document that a request for a referral for professional care will be provided by the research staff. To protect against any misuse of knowledge about study participation, participants will be informed in the informed consent document that employers or insurers could act negatively if they learned of the study participation. Furthermore, participants will be informed that they may choose not to tell their health care providers or insurers about their study participation. Participants will also be told that the study will be covered by a federal certificate of confidentiality, which protects against subpoenas of the research materials.

3) Potential Benefits of the Proposed Research to the Subjects and Others:

There are minimal risks associated with participation in this protocol. Even though most subjects will derive little immediate benefit from participating in this study, they will receive both glucose and lipid evaluations, physical exams, and routine medical screenings that may supplement their usual level of clinical care, as well as compensation for their time and inconvenience. The potential benefits include gaining a better understanding of the effects of antipsychotic medications, glucose and lipid metabolism and adiposity in CD that may ultimately improve our ability to prevent and/or manage the adverse effects of newer, and otherwise beneficial, antipsychotic treatments as well as benefits from the knowledge that they have contributed to learning about childhood onset emotional illness. Such benefits far outweigh the relatively small risks involved in this protocol.

4) Importance of the Knowledge to be Gained:

This study will provide a much-needed understanding of the long-term effects of antipsychotic medications on glucose regulation, and ways to address the risk of diabetes and other cardiovascular disease in young patients treated with antipsychotics. Results of this investigation may also help to inform doctors about the risk of treatment-related changes in glucose regulation and cardiovascular risk associated with certain antipsychotic agents. These benefits to society as well as the benefits to the subject of gaining important information about his/her health status from the results of these tests far outweigh the minimal risks involved in this protocol.

Females and Minority Inclusion in Clinical Research

Inclusion of Females:

Females will be included.

Inclusion of Minorities:

All races/ethnicities represented in the St. Louis region will be recruited, and groups will be balanced for ethnicity based on the ethnic composition of the St. Louis area.

Patients will be recruited from clinics and private psychiatrists in the St. Louis area. In past studies at this university, 50% of our subjects have been recruited from St. Louis City (43.8% White, 51.2% Black or African American, 2.0% Asian, and 0.3% American Indian or Alaskan Native, 0.8% other race, 2.0% Hispanic or Latino origin; 2000 Census of Population and Housing, U.S. Census Bureau); and 50% have been recruited from St. Louis County (76.8% White, 19.0% Black or African American, 2.2% Asian and 0.2% American Indian or Alaskan Native; 1.4% Hispanic or Latino origin; 2000 Census of Population and Housing, U.S. Census Bureau). This 50/50 recruitment represents an over sampling of the less populous city population in the St. Louis area, but maintains the generalizability of our samples to most national metropolitan areas. Based on these percentages, the proposed enrollment is as follows: 60.3% White; 35.1% Black or African American; 2.1% Asian; 0.2% American Indian or Alaskan Native, and 1.7% Hispanic or Latino origin. Based on the gender and minority enrollment of past studies in this laboratory, we do not anticipate any difficulty with obtaining a subject sample of this composition using our proposed recruitment techniques. See "Targeted/Planned Enrollment Table" below.

Targeted/Planned Enrollment Table**Study Title: Metabolic Effects of Antipsychotics in Children****Total Planned Enrollment: 325**

TARGETED/PLANNED ENROLLMENT: Number of Subjects			
Ethnic Category	Sex/Gender		
	Females	Males	Total
Hispanic or Latino	1	4	5
Not Hispanic or Latino	109	211	320
Ethnic Category Total of All Subjects*	110	215	325
Racial Categories			
American Indian/Alaska Native	0	1	1
Asian	3	5	8
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	39	77	116
White	68	132	200
Racial Categories: Total of All Subjects *	110	215	325

Principal Investigator/Program Director (Last, First, Middle): Newcomer, John W.

*The "Ethnic Category Total of All Subjects" must be equal to the "Racial Categories Total of All Subjects."

Participation of children

The proposed study is for children and young teenagers. Separate study of this age group is warranted because clinical, developmental, and neurobiological factors are sufficiently different in the pediatric age group.

Data and Safety Monitoring Plan

Although this proposal does not carry significant risk and is not a Phase III clinical intervention study requiring a Data and Safety Monitoring Committee (DMC), we have elected to appoint a committee as an added safeguard for our minor participants.

During the study, we have added extra safety measures and testing for those subjects who have at baseline or who have developed by 12 weeks on study medication the following:

- a) Fasting blood glucose greater than or equal to 100 mg/dL or post-load glucose of greater than or equal to 140 mg/dL by SureStep Pro, Yellow Springs Instrument (YSI) or laboratory plasma glucose assay.
- b) Rapid weight gain of greater than 10% of baseline weight by 6-weeks on study medication.
- c) Increased fasting triglyceride levels of greater than or equal to 250 mg/dL.

Safety monitoring will be enhanced for these subjects by:

- a) Adding fasting blood glucose, fasting blood lipid, TPR & B/P and weight/height/waist circumference measurements at 3–weeks, 9-weeks, or PRN at physician discretion, and
- b) Providing a home study kit to measure urine sugar/ketones plus assess for adverse events that might require immediate treatment or a decision to discontinue study medication.

Subjects who are given the home study kits will be asked to check and document urine sugar and urine ketone measurements weekly or more often as directed. Although urine measurements will not provide the quantitative information provided by home blood glucose monitoring, it will potentially alert the investigators to increases in blood glucose levels above 180mg/dL and the presence of urine ketones. Urine measurements are less invasive for children and families who already facing added challenges of aggressive behavioral issues.

3-month safety visit post study for a subset of subjects completing the 12-week study

To assess end of study recommendations to parents and treating clinicians, a subset of subjects will be evaluated who have had increases in metabolic risk factors (e.g. 10% or greater increase from baseline body weight, fasting triglyceride levels greater than or equal to 250mg/dL at 6 or 12 weeks and /or a fasting or post-load glucose of greater than or equal to 100 mg/dL or 140 mg/dL, respectively, at 6 or 12 weeks). Each subject will be evaluated individually for these criteria at the end of the 12-week study to determine which subjects would meet criteria for an additional safety visit. Those meeting criteria and consenting/assenting would be scheduled for an interim medical history and measurement of weight, height, waist circumference, fasting glucose and fasting lipid profile. Clinically significant abnormal findings would be discussed with the parent(s) and relevant clinicians.

Role of the Committee- The DSMC's principal goal will be to ensure that participant risk-benefit ratio and study integrity are maintained at the highest possible standards. The following definitions and procedures will be used to monitor and follow any adverse events.

Adverse events (AEs) definition

AEs are defined conventionally as any untoward medical occurrence during the planned observation period in a research participant that develops during participation in the study. The AE and study participation do not have to be causally related.

391 **Serious adverse events (SAEs) definition**

392 SAEs are also defined conventionally, as any medical occurrence that results in death, is life
393 threatening, requires inpatient hospitalization, results in persistent or significant disability, is a congenital
394 anomaly or birth defect, or is an event requiring medical intervention to prevent any of these examples of an
395 SAE.

396 SAEs may be mild (transient, easily tolerated by the participant), moderate (causes discomfort or
397 interrupts the study or the participant's usual activities), or severe (causes considerable interference with usual
398 activities) in severity.

399
400 **Causality of adverse events**

401 The causality of each AE in terms of relationship to administration of test drug will be assessed as
402 definite (reasonable temporal relationship, with or without supporting laboratory data), probable (reasonable
403 temporal relationship and other possible causes can be reasonably excluded), possible (reasonable temporal
404 relationship and other possible causes are at least as or more likely), and unrelated (temporal relationship is
405 not reasonable or other causes are reasonably more likely).

406
407 **Collecting/reporting of adverse events**

408 In the study, all adverse experiences, whether expected or unexpected, will be reported to the DSMC.
409 Any adverse experience that occurs to a greater severity than expected will be reported to the Washington
410 University Institutional Review Board (IRB) and the General Clinical Research Center (GCRC), and to the
411 National Institutes of Health (NIH).

412 The IRB, GCRC, and the GCRC Research Subject Advocate (RSA), will be notified of any serious
413 adverse experience within ten working days of occurrence.

414 If the event is fatal or life threatening, the DSMC, IRB, and RSA will be notified immediately, but not
415 more than 24 hours after occurrence. The GCRC and NIH will be notified by telephone no later than three days
416 after occurrence.

417 The IRB, GCRC, and NIH will receive annual reports regarding all adverse experiences.
418
419

420 **Follow-up of serious adverse events**

421 All SAEs will be followed until resolution or permanent outcome of the event or until stabilization. Some
422 SAEs will require study discontinuation. For example, individual participants will discontinue the study in the
423 rare case they develop diabetes mellitus, or experience triglyceride elevation of 400 mg/dl or greater. These
424 participants will continue to undergo follow-up evaluation by the investigators, direct consultation between the
425 investigators and the treating physicians and establishment of ongoing care plans. For subjects experiencing
426 an SAE that does not require study discontinuation, continuing study participation will require discussions of
427 the potential risks and benefits of continuing participation, involving the participant and their caregivers, the
428 investigators, and the participant's treating physicians.
429
430

431 **Follow-up of adverse events**

432 Appropriate steps will be taken to minimize any AE. Specific examples include:

- 433 ■ Fasting blood sugar elevation above 99 mg/dl, but less than 126 mg/dl. In this case, participants will be
434 monitored on a weekly, biweekly, or PRN basis for further increases in fasting blood sugar.
- 435 ■ Fasting triglyceride elevations above 250 mg/dl, but less than 400 mg/dl. In this case, participants will
436 be monitored on a weekly, biweekly, or PRN basis for further increases in fasting triglycerides.
- 437 ■ Increase from baseline body weight of 10% or more. In this case, participants will be monitored on a
438 weekly, biweekly, or PRN basis for other AEs that may occur in the setting of weight gain, especially
439 hyperglycemia and hyperlipidemia.

440
441 **DSMC Activities**
442

Principal Investigator/Program Director (Last, First, Middle): Newcomer, John W.

The DSMC will include senior clinicians and investigators with expertise in child psychiatry, pediatrics, and statistics (see **Membership** below). The committee will make recommendations to ensure data integrity and the safety of the volunteers. DSMC activities will include:

- Review the research protocol and approve plans for data and safety monitoring.
- Evaluate the progress of the study, including periodic assessments of data quality and timeliness, participant recruitment, accrual and retention, participant risk versus benefit, and other factors that can affect study outcome. Monitoring will also consider factors external to the study when interpreting the data, such as scientific or therapeutic developments that may have an impact on the safety of the participants or the ethics of the study. The principal investigator will make available to the DSMC any newly published information related to the use of atypical antipsychotic medications or the performance of the study procedures in adults or children that may affect patient safety.
- Issues regarding feasibility of the study will be evaluated by the DSMC who will make recommendations to NIH as needed regarding continuation of the study.
- Make recommendations to Washington University School of Medicine, its IRB, and investigators concerning continuation or conclusion of the study.
- Submission of an annual report to the IRB.
- Protect the confidentiality of the trial data and the results of monitoring.
- Review of data and safety issues (including any and all adverse events).
- The DSMC will be empowered to stop the study, at their discretion, for safety reasons.

DSMC Meeting Frequency

The DSMC will meet to review above listed information quarterly, with frequency to be adjusted as needed by the DSMC.

Stopping Rules:

- The study may be discontinued at any time during the study at the recommendation of the DSMC, IRB or NIH.
- If the study is terminated for any reason, the investigators will promptly inform the participants and provide appropriate therapy and follow-up.
- The study will be stopped *for any individual participant* in the case of any SAE which the PI or DSMC determines would be a contraindication to study participation. Noted above, if a participant is withdrawn from the study because of an adverse event, the participant will be followed and treated by the investigators until the abnormal parameter or symptom has resolved or stabilized, and care appropriately transitioned to the primary treating physician.
- New recruitment/enrollment will be discontinued after any SAE until satisfactorily reviewed by the DSMC, with recommendations, if any, for changes to recruitment practices, the informed consent document, or safety/monitoring practices. All such recommendations will be communicated to the GCRC and IRB.

Membership

The DSMC membership has been restricted to individuals free of apparent significant conflicts of interest. The membership for this DSMC is comprised of:

- George Vogler, PhD, Director, Center for Developmental and Health Genetics, Professor of Biobehavioral Health, Pennsylvania State University, with expertise in statistical analysis.
- Gordon Bloomberg, MD, Associate Professor of Pediatrics, Division of Allergy and Pulmonary Medicine, Washington University School of Medicine.
- TENTATIVE NEW MEMBER: Robert Berkowitz, MD, Chair, Department of Child and Adolescent Psychiatry, Children's Hospital of Pennsylvania; Associate Professor of Psychiatry; Attending Psychiatry, Weight and Eating Disorders Program.

Principal Investigator/Program Director (Last, First, Middle): Newcomer, John W.

497
498
499

F. Vertebrate Animals: N/A

G: Literature Cited:

1. Koller E, Malozowski S, Doraiswamy PM. Atypical antipsychotic drugs and hyperglycemia in adolescents. *JAMA*. 2001 Nov 28;286(20):2547-2548.
2. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. *Am J Med*. 2001 Dec 15;111(9):716-723.
3. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. *Pharmacotherapy*. 2003;23(6):735-744.
4. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. *Pharmacotherapy*. 2002;22(7):841-852.
5. Haupt DW, Newcomer JW. Abnormalities in glucose regulation associated with mental illness and treatment. *J Psychosom Res*. 2002;53(4):925-933.
6. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. *J Clin Psych*. 2004;In Press.
7. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. *Diabetes Care*. 2004;27(2):596-558.
8. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2000. *US Department of Health and Human Services*. 2002.
9. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. *JAMA*. 2001;286(10):1195-1200.
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA*. 2002;287(3):356-359.
11. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The Metabolic Syndrome: Prevalence and Associated Risk Factor Findings in the US Population From the Third National Health and Nutrition Examination Survey, 1988-1994. *Arch Intern Med*. 2003;163(4):427-436.
12. National Cholesterol Education Program. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*. 2001;285(19):2486-2497.
13. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. *Obes Res*. 1998;6(suppl 2):51S-209S.
14. Hodgson TA, Cohen AJ. Medical care expenditures for diabetes, its chronic complications, and its comorbidities. *Prev Med*. 1999;29(3):173-186.
15. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. *Diabetes Care*. 1998;21:296-306.
16. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. *JAMA*. 2003;289(2):187-193.
17. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. *Diabetes Care*. 1998 Apr;21(4):518-524.
18. Scheidt-Nave C, Barrett-Connor E, Wingard DL, Cohn BA, Edelstein SL. Sex differences in fasting glycemia as a risk factor for ischemic heart disease death. *Am J Epidemiol*. 1991 Mar 15;133(6):565-576.
19. Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S. GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo Study. *Diabetes Care*. 1996 May;19(5):450-456.
20. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. *Lancet*. 1980 Jun 28;1(8183):1373-1376.
21. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. *Br Med J*. 1983 Sep 24 (Clin Res Ed) 1983 Sep 24;287(6396):867-870.

- 552 22. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident
553 cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783
554 individuals followed for 12.4 years. *Diabetes Care*. 1999 Feb;22(2):233-240.
- 555 23. Gerstein HC. Is glucose a continuous risk factor for cardiovascular mortality? *Diabetes Care*. 1999
556 May;22(5):659-660.
- 557 24. Despres JP, Marette A. Relation of components of insulin resistance syndrome to coronary disease
558 risk. *Curr Opin Lipidol*. 1994 Aug;5(4):274-289.
- 559 25. Austin MA. Plasma triglyceride and coronary heart disease. *Arterioscler Thromb*. 1991 Jan-Feb;11(1):2-
560 14.
- 561 26. Semenkovich CF. Hypertriglyceridemia and combined hyperlipidemia. In: Callow AD, B EC, eds.
562 *Vascular surgery: theory and practice*. Stamford, Connecticut: Appleton & Lange; 1995:105-117.
- 563 27. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and
564 hypertension. *Arch Intern Med*. 1989 Jul;149(7):1514-1520.
- 565 28. Albrink MJ, Krauss RM, Lindgrem FT, von der Groeben J, Pan S, Wood PD. Intercorrelations among
566 plasma high density lipoprotein, obesity and triglycerides in a normal population. *Lipids*.
567 1980;15(9):668-676.
- 568 29. Terry RB, Wood PD, Haskell WL, Stefanick ML, Krauss RM. Regional adiposity patterns in relation to
569 lipids, lipoprotein cholesterol, and lipoprotein subfraction mass in men. *J Clin Endocrinol Metab*.
570 1989;68(1):191-199.
- 571 30. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in
572 individuals with small, dense low density lipoprotein particles. *J Clin Invest*. 1993;92(1):141-146.
- 573 31. Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalence of hypertension and
574 dyslipidemia. *Obes Res*. 2000;8(9):605-619.
- 575 32. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of
576 atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular
577 Munster study. *Am J Cardiol*. 1992;70(7):733-737.
- 578 33. Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart
579 disease: epidemiology, patho-physiology and therapeutic aspects. *Diabetes Metab*. 1999;25(3):199-
580 211.
- 581 34. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant
582 independent risk factor in coronary artery disease. *Eur Heart J*. 1998;19 Suppl M:M8-14.
- 583 35. Austin MA. Epidemiology of hypertriglyceridemia and cardiovascular disease. *Am J Cardiol*.
584 1999;83(9B):13F-16F.
- 585 36. Eidelman RS, Lamas GA, Hennekens CH. The new National Cholesterol Education Program
586 guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart
587 disease. *Arch Intern Med*. 2002;162(18):2033-2036.
- 588 37. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome
589 phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey,
590 1988-1994. *Arch Pediatr Adolesc Med*. 2003;157(8):821-827.
- 591 38. Lebovitz HE. Type 2 diabetes: an overview. *Clin Chem*. 1999;45(8 Pt 2):1339-1345.
- 592 39. Resnick HE, Valsania P, Halter JB, Lin X. Differential effects of BMI on diabetes risk among black and
593 white Americans. *Diabetes Care*. 1998 Nov;21(11):1828-1835.
- 594 40. Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Relationship of visceral adipose
595 tissue and glucose disposal is independent of sex in black NIDDM subjects. *Am J Physiol*. 1997
596 Aug;273(2 Pt 1):E425-432.
- 597 41. Ohlson LO, Larsson B, Svardsudd K, et al. The influence of body fat distribution on the incidence of
598 diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. *Diabetes*.
599 1985;34(10):1055-1058.
- 600 42. Bruning JC, Gautam D, Burks DJ, et al. Role of Brain Insulin Receptor in Control of Body Weight and
601 Reproduction. *Science*. 2000 Sep 22;289(5487):2122-2125.
- 602 43. Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. *N Engl*
603 *J Med*. 1989 Apr 20;320(16):1060-1068.

- 604 44. Semenkovich CF, Chen SH, Wims M, Luo CC, Li WH, Chan L. Lipoprotein lipase and hepatic lipase
605 mRNA tissue specific expression, developmental regulation, and evolution. *J Lipid Res.* 1989
606 Mar;30(3):423-431.
- 607 45. Vessby B, Selinus I, Lithell H. Serum lipoprotein and lipoprotein lipase in overweight, type II diabetics
608 during and after supplemented fasting. *Arteriosclerosis.* 1985 Jan-Feb;5(1):93-100.
- 609 46. Lithell H, Lindgarde F, Hellsing K, et al. Body weight, skeletal muscle morphology, and enzyme
610 activities in relation to fasting serum insulin concentration and glucose tolerance in 48-year-old men.
611 *Diabetes.* 1981 Jan;30(1):19-25.
- 612 47. Rossner S. Studies on an intravenous fat tolerance test. Methodological, experimental and clinical
613 experiences with Intralipid. *Acta Med Scand Suppl.* 1974;564:1-24.
- 614 48. Knudsen P, Eriksson J, Lahdenpera S, Kahri J, Groop L, Taskinen MR. Changes of lipolytic enzymes
615 cluster with insulin resistance syndrome. Botnia Study Group. *Diabetologia.* 1995 Mar;38(3):344-350.
- 616 49. Pollare T, Vessby B, Lithell H. Lipoprotein lipase activity in skeletal muscle is related to insulin
617 sensitivity. *Arterioscler Thromb.* 1991 Sep-Oct;11(5):1192-1203.
- 618 50. Buitelaar JK. Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and
619 adolescents with mixed diagnoses and aggressive behavior. *J Child Adolesc Psychopharmacol.* 2000
620 Spring;10. 10(1. 1):19-26.
- 621 51. Buitelaar JK, Montgomery SA, van Zwieten-Boot BJ. Conduct disorder: guidelines for investigating
622 efficacy of pharmacological intervention. *Eur Neuropsychopharmacol.* 2003;13(4):305-311.
- 623 52. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind, placebo-
624 controlled study of risperidone in adults with autistic disorder and other pervasive developmental
625 disorders [see comments]. *Arch Gen Psychiatry.* 1998 Jul;55. 55(7. 7):633-641.
- 626 53. Soderstrom H, Rastam M, Gillberg C. A clinical case series of six extremely aggressive youths treated
627 with olanzapine. *Eur Child Adolesc Psychiatry.* 2002;11(3):138-141.
- 628 54. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. Effects of risperidone on conduct and
629 disruptive behavior disorders in children with subaverage IQs. *J Am Acad Child Adolesc Psychiatry.*
630 2002;41(9):1026-1036.
- 631 55. Gerardin P, Cohen D, Mazet P, Flament MF. Drug treatment of conduct disorder in young people. *Eur*
632 *Neuropsychopharmacol.* 2002;12(5):361-370.
- 633 56. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. Double-blind, placebo-controlled study of
634 risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. *Am J*
635 *Psychiatry.* 2002;159(8):1337-1346.
- 636 57. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral
637 problems. *N Engl J Med.* 2002;347(5):314-321.
- 638 58. Yarasheski KE, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated
639 diabetes. *J Acquir Immune Defic Syndr.* 1999;21(3):209-216.
- 640 59. Nolte LA, Yarasheski KE, Kawanaka K, Fisher J, Le N, Holloszy JO. The HIV protease inhibitor
641 indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. *Diabetes.*
642 2001;50(6):1397-1401.
- 643 60. Yarasheski KE, Tebas P, Claxton S, et al. Visceral adiposity, C-peptide levels, and low lipase activities
644 predict HIV-dyslipidemia. *Am J Physiol Endocrinol Metab.* 2003;285(4):E899-905.
- 645 61. Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment. Mechanisms and
646 management. *Drug Saf.* 1996 May;14(5):329-342.
- 647 62. Casey DE. The relationship of pharmacology to side effects. *J Clin Psychiatry.* 1997;58 Suppl 10:55-62.
- 648 63. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research
649 synthesis. *Am J Psychiatry.* 1999 Nov;156(11):1686-1696.
- 650 64. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine-induced weight gain:
651 prevalence and clinical relevance. *Am J Psychiatry.* 1992 Jan;149(1):68-72.
- 652 65. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with
653 clozapine. *Am J Psychiatry.* 1992 May;149(5):689-690.
- 654 66. Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical
655 antipsychotics. *J Clin Psychiatry.* 1998;59 Suppl 12:17-22.

- 656 67. Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with
657 antipsychotic drugs. *Am J Psychiatry*. 1999 Feb;156(2):312-314.
- 658 68. Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B. Olanzapine-induced weight gain. *Ann Clin*
659 *Psychiatry*. 1998 Mar;10(1):39.
- 660 69. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. *Acta*
661 *Psychiatr Scand*. 1999 Jul;100(1):3-16.
- 662 70. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM. Weight gain in adolescents treated with
663 risperidone and conventional antipsychotics over six months. *J Child Adolesc Psychopharmacol*.
664 1998;8(3):151-159.
- 665 71. Zipursky R, Gu H, Green AI, et al. Clinical correlates of weight gain in first episode psychosis patients
666 treated with olanzapine. *Schizophrenia Research*. 2003;60(1):372.
- 667 72. Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-
668 episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. *Am J Psychiatry*.
669 2002 Jun;159(6):1058-1060.
- 670 73. Bustillo JR, Lauriello J, Parker K, et al. Treatment of weight gain with fluoxetine in olanzapine-treated
671 schizophrenic outpatients. *Neuropsychopharmacology*. 2003;28(3):527-529.
- 672 74. Blin O. A comparative review of new antipsychotics. *Can J Psychiatry*. 1999;44(3):235-244.
- 673 75. Penn JV, Martini J, Radka D. Weight gain associated with risperidone [letter]. *J Clin Psychopharmacol*.
674 1996 Jun;16. 16(3. 3):259-260.
- 675 76. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. *Am J Psychiatry*. 1994
676 Jun;151(6):825-835.
- 677 77. Ganguli R. Weight gain associated with antipsychotic drugs. *J Clin Psychiatry*. 1999;60 Suppl 21:20-24.
- 678 78. Masand PS. Weight gain associated with atypical antipsychotics. *J Psychotic Disord*. 1998;2:4-6.
- 679 79. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in
680 the treatment of schizophrenia and other psychotic disorders. *J Clin Psychopharmacol*. 1997
681 Oct;17(5):407-418.
- 682 80. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. *J*
683 *Clin Psychiatry*. 1999 Jun;60(6):358-363.
- 684 81. Jody D, Saha AR, Iwamoto T. Meta-analysis of weight effects with aripiprazole. *Int J*
685 *Neuropsychopharmacol*. 2002;5(suppl 1):S186.
- 686 82. Stock E, Marder SR, Saha AR. Safety and tolerability meta-analysis of aripiprazole in schizophrenia. *Int*
687 *J Neuropsychopharmacol*. 2002;5(suppl 1):S185.
- 688 83. Carson WH, Pigott TA, Saha AR. Aripiprazole vs. placebo in the treatment of chronic schizophrenia. *Int*
689 *J Neuropsychopharmacol*. 2002;5(suppl 1):S187.
- 690 84. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus
691 placebo in patients with schizophrenia and schizoaffective disorder. *J Clin Psychiatry*. 2002;63(9):763-
692 771.
- 693 85. Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman-Qua H, van Engeland H. Open-label study
694 of olanzapine in children with pervasive developmental disorder. *J Clin Psychopharmacol*.
695 2002;22(5):455-460.
- 696 86. Ercan ES, Kutlu A, Varan A, Cikoglu S, Coskunol H, Bayraktar E. Olanzapine treatment of eight
697 adolescent patients with psychosis. *Hum Psychopharmacol*. 2004;19(1):53-56.
- 698 87. Patel NC, Kistler JS, James EB, Crismon ML. A retrospective analysis of the short-term effects of
699 olanzapine and quetiapine on weight and body mass index in children and adolescents.
700 *Pharmacotherapy*. 2004;24(7):824-830.
- 701 88. Scahill L, Leckman JF, Schultz RT, Katsoyich L, Peterson BS. A placebo-controlled trial of risperidone
702 in Tourette syndrome. *Neurology*. 2003;60(7):1130-1135.
- 703 89. Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a
704 randomized, double-blind, crossover trial. *J Am Acad Child Adolesc Psychiatry*. 2004;43(2):206-214.
- 705 90. Gagliano A, Germano E, Pustorino G, et al. Risperidone treatment of children with autistic disorder:
706 effectiveness, tolerability, and pharmacokinetic implications. *J Child Adolesc Psychopharmacol*.
707 2004;14(1):39-47.

- 708 91. Martin A, Scahill L, Anderson GM, et al. Weight and leptin changes among risperidone-treated youths
709 with autism: 6-month prospective data. *Am J Psychiatry*. 2004;161(6):1125-1127.
- 710 92. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone,
711 olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
712 *Neuropsychopharmacology*. 2004;29(1):133-145.
- 713 93. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. *J Clin Psychiatry*. 2001
714 Dec;62(Supplement 27):15-26.
- 715 94. Keskiner A. A long-term follow-up of fluphenazine enanthate treatment. *Curr Ther Res Clin Exp*. 1973
716 Jun;15(6):305-313.
- 717 95. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired
718 glucose tolerance in patients treated with clozapine compared with patients treated with conventional
719 depot neuroleptic medications. *J Clin Psychiatry*. 1998 Jun;59(6):294-299.
- 720 96. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE. Clozapine and associated diabetes mellitus. *J*
721 *Clin Psychiatry*. 1997 Mar;58(3):108-111.
- 722 97. Peterson GA, Byrd SL. Diabetic ketoacidosis from clozapine and lithium cotreatment [letter]. *Am J*
723 *Psychiatry*. 1996 May;153(5):737-738.
- 724 98. Ai D, Roper TA, Riley JA. Diabetic ketoacidosis and clozapine. *Postgrad Med J*. 1998 Aug;74(874):493-
725 494.
- 726 99. Kamran A, Doraiswamy PM, Jane JL, Hammett EB, Dunn L. Severe hyperglycemia associated with
727 high doses of clozapine [letter]. *Am J Psychiatry*. 1994 Sep;151(9):1395.
- 728 100. Kostakoglu AE, Yazici KM, Erbas T, Guvener N. Ketoacidosis as a side-effect of clozapine: a case
729 report. *Acta Psychiatr Scand*. 1996 Mar;93(3):217-218.
- 730 101. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment [letter]. *Am*
731 *J Psychiatry*. 1994 Oct;151(10):1520-1521.
- 732 102. Smith H, Kenney-Herbert J, Knowles L. Clozapine-induced diabetic ketoacidosis [letter]. *Aust N Z J*
733 *Psychiatry*. 1999 Feb;33(1):120-121.
- 734 103. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset
735 diabetes. *Biol Psychiatry*. 1998 Oct 15;44(8):778-783.
- 736 104. Yazici KM, Erbas T, Yazici AH. The effect of clozapine on glucose metabolism. *Exp Clin Endocrinol*
737 *Diabetes*. 1998;106(6):475-477.
- 738 105. McDonnell ME, Ruderman NB. Cutting the Gordian knot. Addition of metformin to insulin therapy in a
739 patient with uncontrolled diabetes and schizophrenia [letter]. *Diabetes Care*. 1999 Nov;22(11):1912-
740 1913.
- 741 106. Mohan D, Gordon H, Hindley N, Barker A. Schizophrenia and diabetes mellitus [letter]. *Br J Psychiatry*.
742 1999 Feb;174:180-181.
- 743 107. Colli A, Cocciolo M, Francobandiera F, Rogantin F, Cattalini N. Diabetic ketoacidosis associated with
744 clozapine treatment [letter]. *Diabetes Care*. 1999 Jan;2(1):176-177.
- 745 108. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid
746 abnormalities: A five-year naturalistic study. *Am J Psychiatry*. 2000 Jun;157(6):975-981.
- 747 109. Wehring H, Alexander B, Perry PJ. Diabetes mellitus associated with clozapine therapy.
748 *Pharmacotherapy*. 2000 Jul;20(7):844-847.
- 749 110. Melson AK, Selke G, Fucetola R, Schweiger JA, Newcomer JW. Clozapine can change glucose
750 regulation in schizophrenia independent of body mass index (BMI). *Society for Neuroscience Abstracts*.
751 1999;25(2):2074.
- 752 111. Maule S, Giannella R, Lanzio M, Villari V. Diabetic ketoacidosis with clozapine treatment [letter].
753 *Diabetes Nutr Metab*. 1999 Apr;12(2):187-188.
- 754 112. Rigalleau V, Gatta B, Bonnaud S, et al. Diabetes as a result of atypical anti-psychotic drugs--a report of
755 three cases. *Diabet Med*. 2000 Jun;17(6):484-486.
- 756 113. Selke GJ, Newcomer JW, Fucetola R, Cooper BP, Schweiger JA. Atypical antipsychotic-induced
757 differences in glucose regulation in schizophrenia independent of differences in adiposity. *Soc Neurosci*
758 *Abstr*. 2000;26(1):275.
- 759 114. Avram AM, Patel V, Taylor HC, Kirwan JP, Kalhan S. Euglycemic clamp study in clozapine-induced
760 diabetic ketoacidosis. *Ann Pharmacother*. 2001 Nov;35(11):1381-1387.

- 761 115. Pierides M. Clozapine monotherapy and ketoacidosis. *Br J Psychiatry*. 1997 Jul;171:90-91.
- 762 116. Griffiths J, Springuel P. Atypical antipsychotics: impaired glucose metabolism. *CMAJ*. 2001 Oct
- 763 2;165(7):943-945, 947-949.
- 764 117. Dervaux A, Mascarenhas N, Lambomez T. [Importance of blood glucose level when starting
- 765 antipsychotic treatment]. *Presse Med*. 2001 Sep 22;30(26):1298.
- 766 118. Ananth J, Gunatilake S, Aquino S, Bach V, Costa J. Are African American patients at a higher risk for
- 767 olanzapine-induced glucose intolerance? *Psychopharmacology (Berl)*. 2001 Sep;157(3):324-325.
- 768 119. Van Meter SA, Seaburg H, McLendon B, Doraiswamy PM. Olanzapine, new-onset diabetes mellitus,
- 769 and risk for insulin overdose. *J Clin Psychiatry*. 2001 Dec;62(12):993-994.
- 770 120. Johnson RP, Al-Taher MT, Madlock LE, Guo M, Nasdahl CS. Increasing Insulin Dose for Olanzapine-
- 771 Related Diabetes. *Am J Psychiatry*. 2002 Jan 1;159(1):150-151.
- 772 121. Bechara CI, Goldman-Levine JD. Dramatic worsening of type 2 diabetes mellitus due to olanzapine
- 773 after 3 years of therapy. *Pharmacotherapy*. 2001 Nov;21(11):1444-1447.
- 774 122. Seaburg HL, McLendon BM, Doraiswamy PM. Olanzapine-associated severe hyperglycemia,
- 775 ketonuria, and acidosis: case report and review of literature. *Pharmacotherapy*. 2001;21(11):1448-
- 776 1454.
- 777 123. Paizis M, Cavaleri S, Schwarz ME, Levin Z. Acute-onset ketoacidosis during olanzapine treatment in a
- 778 patient without pretreatment obesity or treatment-associated weight gain. *Primary Psychiatry*.
- 779 1999;6(12):37-38.
- 780 124. Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus [letter]. *Am J*
- 781 *Psychiatry*. 1999 Sep;156(9):1471.
- 782 125. Von Hayek D, Huttli V, Reiss J, Schweiger HD, Fuessl HS. [Hyperglycemia and ketoacidosis associated
- 783 with olanzapine]. *Nervenarzt*. 1999 Sep;70(9):836-837.
- 784 126. Fertig MK, Brooks VG, Shelton PS, English CW. Hyperglycemia associated with olanzapine [letter]. *J*
- 785 *Clin Psychiatry*. 1998 Dec;59(12):687-689.
- 786 127. Ober SK, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine [letter]. *Am J Psychiatry*. 1999
- 787 Jun;156(6):970.
- 788 128. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis
- 789 associated with olanzapine treatment. *Psychosomatics*. 1999 Sep-Oct;40(5):438-443.
- 790 129. Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment [letter]. *Diabetes Care*.
- 791 1999 Jun;22(6):1002-1003.
- 792 130. Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine-induced glucose dysregulation. *Ann*
- 793 *Pharmacother*. 2000 Jul-Aug;34(7-8):865-867.
- 794 131. Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case
- 795 report and review of the literature. *J Am Board Fam Pract*. 2001;14(4):278-282.
- 796 132. Selva KA, Scott SM. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. *J*
- 797 *Pediatr*. 2001 Jun;138(6):936-938.
- 798 133. Kropp S, Emrich HM, Bleich S, Degner D. Olanzapine-related hyperglycemia in a nondiabetic woman.
- 799 *Can J Psychiatry*. 2001 Jun;46(5):457.
- 800 134. Bonanno DG, Davydov L, Botts SR. Olanzapine-induced diabetes mellitus. *Ann Pharmacother*. 2001
- 801 May;35(5):563-565.
- 802 135. Sobel M, Jagers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of
- 803 quetiapine treatment [letter]. *J Clin Psychiatry*. 1999 Aug;60(8):556-557.
- 804 136. Wilson D, Hammond C, D'Souza L, Sarkar N. Glucose intolerance with atypical antipsychotics.
- 805 *Schizophr Res*. 2001 Apr;49(Supplement):290.
- 806 137. Procyshyn RM, Pande S, Tse G. New-onset diabetes mellitus associated with quetiapine [letter]. *Can J*
- 807 *Psychiatry*. 2000 Sep;45(7):668-669.
- 808 138. Wirshing DA, Erhart SM, Pierre JM, Boyd JA. Nonextrapyramidal side effects of novel antipsychotics.
- 809 *Curr Opin Psychiatry*. 2000;13:45-50.
- 810 139. Wirshing DA, Pierre JM, Eyeler J, Weinbach J, Wirshing WC. Risperidone-associated new-onset
- 811 diabetes. *Biol Psychiatry*. 2001 Jul 15;50(2):148-149.
- 812 140. Mallya A, Chawla P, Boyer SK, DeRosear L. Resolution of hyperglycemia on risperidone
- 813 discontinuation: a case report. *J Clin Psychiatry*. 2002;63(5):453-454.

- 814 141. Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with risperidone treatment? [letter].
815 *Psychosomatics*. 2000 Jul-Aug;41(4):369-370.
- 816 142. Haupt DW, Newcomer JW. Risperidone-associated diabetic ketoacidosis. *Psychosomatics*. 2001
817 Jun;42:279-280.
- 818 143. Yang SH, McNeely MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. *Am J*
819 *Psychiatry*. 2002;159(8):1435.
- 820 144. Pfizer. Study 054. *FDA Website*.
- 821 145. Glick ID, Fryburg D, O'Sullivan RL, Siu C, Simpson GM. Ziprasidone's benefits versus olanzapine on
822 weight gain and insulin resistance. *American Psychiatric Association 154th Annual Meeting, May 2001,*
823 *New Orleans, LA, Abstract #NR261*. 2001.
- 824 146. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model
825 assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin
826 concentrations in man. *Diabetologia*. 1985 Jul;28(7):412-419.
- 827 147. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. *Diabetes*
828 *Care*. 1997 Jul;20(7):1087-1092.
- 829 148. Domon SE, Webber JC. Hyperglycemia and hypertriglyceridemia secondary to olanzapine. *J Child*
830 *Adolesc Psychopharmacol*. 2001;11(3):285-288.
- 831 149. Domon SE, Cargile CS. Quetiapine-associated hyperglycemia and hypertriglyceridemia. *J Am Acad*
832 *Child Adolesc Psychiatry*. 2002;41(5):495-496.
- 833 150. Bloch Y, Vardi O, Mendlovic S, Levkovitz Y, Gothelf D, Ratzoni G. Hyperglycemia from olanzapine
834 treatment in adolescents. *J Child Adolesc Psychopharmacol*. 2003;13(1):97-102.
- 835 151. Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL. Effects of weight loss on regional fat
836 distribution and insulin sensitivity in obesity. *Diabetes*. 1999 Apr;48(4):839-847.
- 837 152. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic
838 treatment of schizophrenia. *Arch Gen Psychiatry*. 2002;59:337-345.
- 839 153. Houseknecht KLR, A. S.
840 Johnson, D. E.
- 841 Rollema, H. Clozapine and olanzapine, but not ziprasidone, cause acute insulin resistance in normal rats. *Biol*
842 *Psychiatry*. 2005;57(8 (Supplement 1)):128S.
- 843 154. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia
844 treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and
845 minimal model analysis. *Arch Gen Psychiatry*. 2005;62(1):19-28.
- 846 155. Ader M, Pacini G, Yang YJ, Bergman RN. Importance of glucose per se to intravenous glucose
847 tolerance. Comparison of the minimal-model prediction with direct measurements. *Diabetes*. 1985
848 Nov;34(11):1092-1103.
- 849 156. Beard JC, Bergman RN, Ward WK, Porte D. The insulin sensitivity index in nondiabetic man.
850 Correlation between clamp-derived and IVGTT-derived values. *Diabetes*. 1986;35(3):362-369.
- 851 157. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man
852 derived by the minimal model method and the euglycemic glucose clamp. *J Clin Invest*.
853 1987;79(3):790-800.
- 854 158. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-
855 model approach. *Diabetes*. 1989 Dec;38(12):1512-1527.
- 856 159. Welch S, Gebhart SS, Bergman RN, Phillips LS. Minimal model analysis of intravenous glucose
857 tolerance test-derived insulin sensitivity in diabetic subjects. *J Clin Endocrinol Metab*. 1990;71(6):1508-
858 1518.
- 859 160. Steil GM, Volund A, Kahn SE, Bergman RN. Reduced sample number for calculation of insulin
860 sensitivity and glucose effectiveness from the minimal model. Suitability for use in population studies.
861 *Diabetes*. 1993;42(2):250-256.
- 862 161. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin
863 secretion and resistance. *Am J Physiol*. 1979 Sep;237(3):E214-223.
- 864 162. Saad MF, Anderson RL, Laws A, et al. A comparison between the minimal model and the glucose
865 clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin
866 Resistance Atherosclerosis Study. *Diabetes*. 1994 Sep;43(9):1114-1121.

- 867 163. Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic
868 schizophrenic patients. *Clin Pharmacol Ther.* 1970 Nov-Dec;11(6):883-889.
- 869 164. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. *Am J Health Syst*
870 *Pharm.* 1996 Sep 1;53(17):2079-2081.
- 871 165. Gaulin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL. Clozapine-associated elevation in serum
872 triglycerides. *Am J Psychiatry.* 1999 Aug;156(8):1270-1272.
- 873 166. Spivak B, Roitman S, Vered Y, et al. Diminished suicidal and aggressive behavior, high plasma
874 norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic
875 patients maintained on clozapine. *Clin Neuropharmacol.* 1998 Jul-Aug;21(4):245-250.
- 876 167. Meyer JM. Novel antipsychotics and severe hyperlipidemia. *American College of*
877 *Neuropsychopharmacology 38th Annual Meeting Scientific Abstracts.* 1999 Dec:211.
- 878 168. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. *J*
879 *Clin Psychiatry.* 1999 Nov;60(11):767-770.
- 880 169. Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C. Olanzapine-induced elevation of plasma
881 triglyceride levels [letter]. *Am J Psychiatry.* 1999 Sep;156(9):1471-1472.
- 882 170. L'Italien GJ. Pharmacoeconomic impact of antipsychotic-induced metabolic events. *Am J Manag Care.*
883 2003;3(2):S38-S42.
- 884 171. Nguyen M, Murphy T. Olanzapine and hypertriglyceridemia. *J Am Acad Child Adolesc Psychiatry.*
885 2001;40(2):133.
- 886 172. Egusa G, Beltz WF, Grundy SM, Howard BV. Influence of obesity on the metabolism of apolipoprotein
887 B in humans. *J Clin Invest.* 1985 Aug;76(2):596-603.
- 888 173. Tobey TA, Greenfield M, Kraemer F, Reaven GM. Relationship between insulin resistance, insulin
889 secretion, very low density lipoprotein kinetics, and plasma triglyceride levels in normotriglyceridemic
890 man. *Metabolism.* 1981 Feb;30(2):165-171.
- 891 174. Howard BV. Lipoprotein metabolism in diabetes mellitus. *J Lipid Res.* 1987 Jun;28(6):613-628.
- 892 175. BJC Health System. *Drug Formulary, 200-2001.* Hudson, OH: Lexi-Comp, Inc.; 2000.
- 893 176. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify
894 overweight individuals who are insulin resistant. *Ann Intern Med.* 2003;139(10):802-809.
- 895 177. Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best
896 simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related
897 cardiovascular risk in men and women. *Am J Cardiol.* 1994 Mar 1;73(7):460-468.
- 898 178. Kamel EG, McNeill G, Van Wijk MC. Usefulness of anthropometry and DXA in predicting intra-
899 abdominal fat in obese men and women. *Obes Res.* 2000 Jan;8(1):36-42.
- 900 179. van der Kooy K, Leenen R, Seidell JC, Deurenberg P, Visser M. Abdominal diameters as indicators of
901 visceral fat: comparison between magnetic resonance imaging and anthropometry. *Br J Nutr.* 1993
902 Jul;70(1):47-58.
- 903 180. Jensen MD, Kanaley JA, Roust LR, et al. Assessment of body composition with use of dual-energy x-
904 ray absorptiometry: evaluation and comparison with other methods. *Mayo Clin Proc.* 1993;68(9):867-
905 873.
- 906 181. Heymsfield SB, Smith R, Aulet M, et al. Appendicular skeletal muscle mass: measurement by dual-
907 photon absorptiometry. *Am J Clin Nutr.* 1990;52(2):214-218.
- 908 182. Abate N, Burns D, Peshock RM, Garg A, Grundy SM. Estimation of adipose tissue mass by magnetic
909 resonance imaging: validation against dissection in human cadavers. *J Lipid Res.* 1994
910 Aug;35(8):1490-1496.
- 911 183. McGuire EA, Helderan JH, Tobin JD, Andres R, Berman M. Effects of arterial versus venous
912 sampling on analysis of glucose kinetics in man. *J Appl Physiol.* 1976;41(4):565-573.
- 913 184. Jensen MD, Nielsen S. Insulin dose response analysis of free fatty acid kinetics. *Metabolism.*
914 2007;56(1):68-76.
- 915 185. Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during
916 hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous
917 glucose infusates. *Diabetes.* 1987 Aug;36(8):914-924.

- 918 186. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is
919 directly related to intrahepatic triglyceride content in obese subjects. *Gastroenterology*.
920 2008;134(5):1369-1375.
- 921 187. Deivanayagam S, Mohammed BS, Vitola BE, et al. Nonalcoholic fatty liver disease is associated with
922 hepatic and skeletal muscle insulin resistance in overweight adolescents. *Am J Clin Nutr*.
923 2008;88(2):257-262.
- 924 188. Magkos F, Mittendorfer B. Stable isotope-labeled tracers for the investigation of fatty acid and
925 triglyceride metabolism in humans in vivo. *Clin Lipidol*. 2009;4(2):215-230.
- 926 189. Howie SR. Blood sample volumes in child health research: review of safe limits. *Bull World Health
927 Organ*. 2011;89(1):46-53.
- 928 190. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity
929 from the oral glucose tolerance test. *Diabetes Care*. 2001;24(3):539-548.
- 930 191. Tillman R, Geller B, Craney JL, Bolhofner K, Williams M, Zimmerman B. Relationships of parent and child
931 informants to prevalence of mania symptoms in children with a prepubertal and early adolescent
932 bipolar disorder phenotype. *Am J Psychiatry*. In press.
- 933 192. Herjanic B, Reich W. Development of a structured psychiatric interview for children: agreement
934 between child and parent on individual symptoms. *J Abnorm Child Psychol*. 1982;10(3):307-324.
- 935 193. Weissman MM, Wickramaratne P, Warner V, et al. Assessing psychiatric disorders in children.
936 Discrepancies between mothers' and children's reports. *Arch Gen Psychiatry*. 1987;44(8):747-753.
- 937 194. Angold A, Weissman MM, John K, et al. Parent and child reports of depressive symptoms in children at
938 low and high risk of depression. *J Child Psychol Psychiatry*. 1987;28(6):901-915.
- 939 195. Jensen PS, Rubio-Stipec M, Canino G, et al. Parent and child contributions to diagnosis of mental
940 disorder: are both informants always necessary? *J Am Acad Child Adolesc Psychiatry*.
941 1999;38(12):1569-1579.
- 942 196. Grills AE, Ollendick TH. Multiple informant agreement and the anxiety disorders interview schedule for
943 parents and children. *J Am Acad Child Adolesc Psychiatry*. 2003;42(1):30-40.
- 944 197. Ivens C, Rehm LP. Assessment of childhood depression: correspondence between reports by child,
945 mother, and father. *J Am Acad Child Adolesc Psychiatry*. 1988;27(6):738-747.
- 946 198. Mokros HB, Poznanski E, Grossman JA, Freeman LN. A comparison of child and parent ratings of
947 depression for normal and clinically referred children. *J Child Psychol Psychiatry*. 1987;28(4):613-624.
- 948 199. Nguyen N, Whittlesey S, Scimeca K, et al. Parent-child agreement in prepubertal depression: findings
949 with a modified assessment method. *J Am Acad Child Adolesc Psychiatry*. 1994;33(9):1275-1283.
- 950 200. Bird HR, Gould MS, Staghezza B. Aggregating data from multiple informants in child psychiatry
951 epidemiological research. *J Am Acad Child Adolesc Psychiatry*. 1992;31(1):78-85.
- 952 201. Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults,. Expert Panel of the
953 Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection,
954 Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Text in box
955 on page 2489, fifth bullet point, concerning drugs that increase LDL cholesterol and decrease HDL
956 cholesterol. *JAMA*. 2001;285(19):2489.
- 957 202. Aman M, Singh N. Aberrant Behavior Checklist (ABC) - Community Supplementary Manual (1994).
958 1994.
- 959 203. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale
960 for the assessment of treatment effects. *Am J Ment Defic*. 1985;89(5):485-491.
- 961 204. Gogtay N, Odonez A, Herman DH, et al. Dynamic mapping of cortical development before and after
962 the onset of pediatric bipolar illness. *J Child Psychol Psychiatry*. 2007;48(9):852-862.
- 963 205. Marshburn EC, Aman MG. Factor validity and norms for the aberrant behavior checklist in a community
964 sample of children with mental retardation. *J Autism Dev Disord*. 1992;22(3):357-373.
- 965 206. Brown EC, Aman MG, Havercamp SM. Factor analysis and norms for parent ratings on the Aberrant
966 Behavior Checklist-Community for young people in special education. *Res Dev Disabil*. 2002;23(1):45-
967 60.
- 968 207. Shaffer D, Gould MS, Brasic J, et al. A children's global assessment scale (CGAS). *Arch Gen
969 Psychiatry*. 1983;40(11):1228-1231.

208. Bird HR, Canino G, Rubio-Stipec M, Ribera JC. Further measures of the psychometric properties of the Children's Global Assessment Scale. *Arch Gen Psychiatry*. 1987;44(9):821-824.
209. Guy W. *ECDEU Assessment Manual for Psychopharmacology*. Rockville, MD: US Department of Health, Education and Welfare; 1976.
210. Duke PM, Litt IF, Gross RT. Adolescents' self-assessment of sexual maturation. *Pediatrics*. 1980;66(6):918-920.
211. O'Loughlin J, Paradis G, Renaud L, Meshefedjian G, Gray-Donald K. Prevalence and correlates of overweight among elementary schoolchildren in multiethnic, low income, inner-city neighbourhoods in Montreal, Canada. *Ann Epidemiol*. 1998;8(7):422-432.
212. Stevens J, Cornell CE, Story M, et al. Development of a questionnaire to assess knowledge, attitudes, and behaviors in American Indian children. *Am J Clin Nutr*. 1999;69(4 Suppl):773S-781S.
213. Economos CD, Sacheck JM, Kwan Ho Chui K, et al. School-based behavioral assessment tools are reliable and valid for measurement of fruit and vegetable intake, physical activity, and television viewing in young children. *J Am Diet Assoc*. 2008;108(4):695-701.
214. Sallis JF, Condon SA, Goggin KJ, Roby JJ, Kolody B, Alcaraz JE. The development of self-administered physical activity surveys for 4th grade students. *Res Q Exerc Sport*. 1993;64(1):25-31.
215. Paradis G, Levesque L, Macaulay AC, et al. Impact of a diabetes prevention program on body size, physical activity, and diet among Kanien'keha:ka (Mohawk) children 6 to 11 years old: 8-year results from the Kahnawake Schools Diabetes Prevention Project. *Pediatrics*. 2005;115(2):333-339.
216. Nelson MC, Lytle LA. Development and evaluation of a brief screener to estimate fast-food and beverage consumption among adolescents. *J Am Diet Assoc*. 2009;109(4):730-734.
217. Nelson MC, Neumark-Sztainer D, Hannan PJ, Story M. Five-year longitudinal and secular shifts in adolescent beverage intake: findings from project EAT (Eating Among Teens)-II. *J Am Diet Assoc*. 2009;109(2):308-312.
218. Veugelers PJ, Fitzgerald AL. Prevalence of and risk factors for childhood overweight and obesity. *CMAJ*. 2005;173(6):607-613.
219. Borradaile KE, Foster GD, May H, et al. Associations between the Youth/Adolescent Questionnaire, the Youth/Adolescent Activity Questionnaire, and body mass index z score in low-income inner-city fourth through sixth grade children. *Am J Clin Nutr*. 2008;87(6):1650-1655.
220. Levesque L, Guilbault G, Delormier T, Potvin L. Unpacking the black box: a deconstruction of the programming approach and physical activity interventions implemented in the Kahnawake Schools Diabetes Prevention Project. *Health Promot Pract*. 2005;6(1):64-71.
221. Bennett DS, Power TJ, Rostain AL, Carr DE. Parent acceptability and feasibility of ADHD interventions: assessment, correlates, and predictive validity. *J Pediatr Psychol*. 1996;21(5):643-657.
222. Post RM, Leverich GS, Fergus E, Miller R, Luckenbaugh D. Parental attitudes towards early intervention in children at high risk for affective disorders. *J Affect Disord*. 2002;70(2):117-124.
223. Soley G, Marshall R, Chambliss C. *Training therapists about client expectations of psychotherapy. Research report. Ursinus College*. 2000.
224. Johnston C, Seipp C, Hommersen P, Hoza B, Fine S. Treatment choices and experiences in attention deficit and hyperactivity disorder: relations to parents' beliefs and attributions. *Child Care Health Dev*. 2005;31(6):669-677.
225. Jorm AF, Morgan AJ, Wright A. A comparison of clinician, youth, and parent beliefs about helpfulness of interventions for early psychosis. *Psychiatr Serv*. 2008;59(10):1115-1120.
226. Moos RH, Moos BS. *Family Environment Scale Manual: Development, Applications, Research. A social climate scale. Fourth edition. Center for Health Care Evaluation. Department of Psychiatry and Behavioral Sciences. Stanford University School of Medicine. Available at: <http://www.mindgarden.com/>. . Palo Alto, California*2009.
227. Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH. Determination of free and total insulin and C-peptide in insulin-treated diabetics. *Diabetes*. 1977 Jan;26(1):22-29.
228. Ensink J. Immunoassays for glucagon. In: Lefebvre P, ed. *Handbook of Experimental Pharmacology*. Vol 66. New York: Springer Verlag; 1983:203-221.
229. Farmer RW, Pierce CE. Plasma cortisol determination: radioimmunoassay and competitive protein binding compared. *Clin Chem*. 1974 Apr;20(4):411-414.

Principal Investigator/Program Director (Last, First, Middle): Newcomer, John W.

- 023 230. Shah SD, Clutter WE, Cryer PE. External and internal standards in the single-isotope derivative
024 (radioenzymatic) measurement of plasma norepinephrine and epinephrine. *J Lab Clin Med.* 1985
025 Dec;106(6):624-629.
- 026 231. Patterson BW, Hachey DL, Cook GL, Amann JM, Klein PD. Incorporation of a stable isotopically
027 labeled amino acid into multiple human apolipoproteins. *J Lipid Res.* 1991 Jul;32(7):1063-1072.
- 028 232. Patterson BW, Zhao G, Elias N, Hachey DL, Klein S. Validation of a new procedure to determine
029 plasma fatty acid concentration and isotopic enrichment. *J Lipid Res.* 1999 Nov;40(11):2118-2124.
- 030 233. Elias N, Patterson BW, Schonfeld G. Decreased production rates of VLDL triglycerides and ApoB-100
031 in subjects heterozygous for familial hypobetalipoproteinemia. *Arterioscler Thromb Vasc Biol.* 1999
032 Nov;19(11):2714-2721.
- 033 234. Elias N, Patterson BW, Schonfeld G. In vivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a
034 form of hypobetalipoproteinemia not linked to the ApoB gene. *Arterioscler Thromb Vasc Biol.* 2000
035 May;20(5):1309-1315.
- 036 235. Patterson BW, Zhao G, Klein S. Improved accuracy and precision of gas chromatography/mass
037 spectrometry measurements for metabolic tracers. *Metabolism.* 1998 Jun;47(6):706-712.
- 038 236. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. *Ann NY Acad*
039 *Sci.*82:420-430.
- 040 237. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. *J Appl Physiol.* 1983
041 Aug;55(2):628-634.
- 042
- 043
- 044